

Pembrolizumab in patients with advanced hepatocellular carcinoma treated with sorafenib (KEYNOTE-224): a non-randomised, open-label, phase 3 trial

Lancet Oncology, The

19, 940-952

DOI: [10.1016/s1470-2045\(18\)30351-6](https://doi.org/10.1016/s1470-2045(18)30351-6)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 89-89.	1.5	30
3	Understanding and quantifying the immune microenvironment in hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 107-107.	1.5	1
4	Systemic Therapy for Hepatocellular Carcinoma: Recent Advances. <i>Acta Hepatologica Japonica</i> , 2018, 59, 587-603.	0.0	3
5	Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1â€6 hepatocellular carcinoma model. <i>Cancer Science</i> , 2018, 109, 3993-4002.	1.7	215
6	Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 91-98.	1.8	10
7	Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 155, 1936-1950.e17.	0.6	211
8	Immunotherapy for hepatocellular carcinoma: current status and future perspectives. <i>ESMO Open</i> , 2018, 3, e000455.	2.0	76
9	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. <i>Theranostics</i> , 2018, 8, 5690-5702.	4.6	45
10	Stereotactic Ablative Radiotherapy (SABR/SBRT) for Hepatocellular Carcinoma. <i>Current Hepatology Reports</i> , 2018, 17, 392-398.	0.4	1
11	Systemic treatment for hepatocellular carcinoma. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 148-155.	0.9	8
12	Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. <i>Cancers</i> , 2018, 10, 367.	1.7	24
13	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv238-iv255.	0.6	663
14	Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. <i>Seminars in Liver Disease</i> , 2018, 38, 379-388.	1.8	62
15	Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies. <i>Clinics</i> , 2018, 73, e510s.	0.6	0
16	Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880808.	1.4	10
17	Current State of Immunotherapy for HCCâ€”Supporting Data and Toxicity Management. <i>Current Hepatology Reports</i> , 2018, 17, 434-443.	0.4	2
18	Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. <i>Cancers</i> , 2018, 10, 412.	1.7	138
19	Nivolumab for the treatment of hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1169-1175.	1.1	99

#	ARTICLE	IF	CITATIONS
20	Molecular heterogeneity in hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2018, 5, HEP10.	4.2	18
21	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. <i>Drugs in Context</i> , 2018, 7, 1-10.	1.0	34
22	Shaping the landscape of immune oncology in hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 855-856.	5.1	2
24	Liquid biopsies for hepatocellular carcinoma. <i>Translational Research</i> , 2018, 201, 84-97.	2.2	29
25	Recent developments with immunotherapy for hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 905-910.	1.4	89
26	Emerging therapies in advanced hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2018, 7, 17.	2.0	85
28	Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 872-884.	1.9	31
29	Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. <i>Future Oncology</i> , 2019, 15, 2449-2462.	1.1	11
30	Immunotherapy for hepatocellular carcinoma: Current and future. <i>World Journal of Gastroenterology</i> , 2019, 25, 2977-2989.	1.4	148
31	Prevention Strategies for Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 255-289.	0.4	2
32	Early alpha-fetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2184-2189.	1.9	55
33	Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 2416-2429.	1.4	66
34	Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib. <i>Digestive and Liver Disease</i> , 2019, 51, 1488-1490.	0.4	9
35	Experimental Models for Preclinical Research in Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 333-358.	0.4	7
36	Letter: programmed cell death protein-1-targeted immunotherapy for advanced hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 340-341.	1.9	1
37	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 480-490.	4.2	57
38	The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2008-2023.	1.9	56
39	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2214-2229.	1.9	327

#	ARTICLE	IF	CITATIONS
40	A global view of hepatocellular carcinoma: trends, risk, prevention and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 589-604.	8.2	2,482
41	Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. <i>Liver Cancer</i> , 2019, 8, 221-238.	4.2	51
42	Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?. <i>Cancers</i> , 2019, 11, 1078.	1.7	36
43	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. <i>Theranostics</i> , 2019, 9, 4678-4687.	4.6	61
44	Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). <i>Cancers</i> , 2019, 11, 1085.	1.7	60
45	Immunotherapeutic approaches in nasopharyngeal carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1165-1172.	1.4	40
46	Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. <i>Seminars in Diagnostic Pathology</i> , 2019, 36, 434-440.	1.0	58
48	The alpha and Òeta in phase II trials hepatocellular carcinoma â€•A tale of more than radiological response?. <i>Liver International</i> , 2019, 39, 1391-1393.	1.9	0
49	Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. <i>World Journal of Gastroenterology</i> , 2019, 25, 3151-3167.	1.4	80
50	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 721-730.	3.7	105
51	Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 588-596.	0.4	43
53	Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. <i>Liver International</i> , 2019, 39, 1608-1621.	1.9	67
54	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. <i>Digestive and Liver Disease</i> , 2019, 51, 1713-1719.	0.4	18
55	Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. <i>Clinical Oncology</i> , 2019, 31, 560-569.	0.6	6
56	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 1390-1395.	1.6	54
57	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 4018-4025.	0.8	118
58	Immune checkpoint inhibitors for hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3312-3319.	2.0	90
59	Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. , 2019, 7, 193.		304

#	ARTICLE	IF	CITATIONS
60	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986269.	1.4	75
61	Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma. <i>BioScience Trends</i> , 2019, 13, 282-283.	1.1	5
62	Immunomodulatory TGF- $\beta$ 2 Signaling in Hepatocellular Carcinoma. <i>Trends in Molecular Medicine</i> , 2019, 25, 1010-1023.	3.5	157
63	&lt;p&gt;Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 119-129.	1.8	15
64	Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein. <i>Nano Letters</i> , 2019, 19, 5266-5276.	4.5	40
65	Treatment Lines in Hepatocellular Carcinoma. <i>Visceral Medicine</i> , 2019, 35, 266-272.	0.5	31
66	Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 861.	1.7	25
67	Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. <i>Cancers</i> , 2019, 11, 873.	1.7	19
68	Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3603-3614.	2.0	121
69	Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 705-715.	2.1	18
70	Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). <i>Oncolimmunology</i> , 2019, 8, 1615817.	2.1	85
71	Comparison of the current international guidelines on the management of HCC. <i>JHEP Reports</i> , 2019, 1, 114-119.	2.6	30
72	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
73	Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Medicina (Lithuania)</i> , 2019, 55, 698.	0.8	54
74	Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1749-1752.	0.5	22
75	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> , 2019, 11, 1554.	1.7	73
76	Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 941-949.	1.9	25
77	Cabozantinib for the treatment of hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 847-855.	1.1	12

#	ARTICLE	IF	CITATIONS
78	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinomaâ€”Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. <i>Cancers</i> , 2019, 11, 1517.	1.7	30
79	<p></p>Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine</p>; <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 151-166.	1.8	25
80	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	1.7	44
81	Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 447.	3.5	149
82	Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway. <i>International Journal of Biological Sciences</i> , 2019, 15, 1905-1920.	2.6	53
83	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. <i>Cancers</i> , 2019, 11, 1721.	1.7	8
84	Immune checkpoint inhibitorâ€”associated pituitaryâ€”adrenal dysfunction: A systematic review and metaâ€”analysis. <i>Cancer Medicine</i> , 2019, 8, 7503-7515.	1.3	35
85	Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 546-548.	0.7	1
86	Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. <i>BMC Cancer</i> , 2019, 19, 1062.	1.1	19
87	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. <i>Current Oncology</i> , 2019, 26, 665-681.	0.9	2
88	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
89	The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2019, 14, 51-55.	1.0	4
90	Emerging agents and regimens for hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 110.	6.9	71
91	Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. <i>Frontiers in Oncology</i> , 2019, 9, 1157.	1.3	75
92	Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 6986-6994.	1.3	37
93	Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 423.	3.5	47
94	Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. <i>Medicina (Lithuania)</i> , 2019, 55, 526.	0.8	147
95	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. <i>Journal of Hepatology</i> , 2019, 71, 1175-1183.	1.8	64

#	ARTICLE	IF	CITATIONS
98	Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4307.	1.8	30
99	PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 51-51.	1.5	16
100	From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 396.	3.5	265
101	The potential combinational immunotherapies for treatment of hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2019, 2, 47-51.	0.2	3
102	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986976.	1.4	31
103	New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2019, 14, 56-61.	1.0	23
104	Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1433.	1.7	13
105	PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 505-510.	0.6	30
106	Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. <i>International Journal of Hyperthermia</i> , 2019, 36, 1002-1010.	1.1	9
107	Adoptive cell transfer therapy for hepatocellular carcinoma. <i>Frontiers of Medicine</i> , 2019, 13, 3-11.	1.5	45
108	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 599-608.	2.0	97
109	Genomic profiling of combined hepatocellular-choleangiocarcinoma reveals similar genetics to hepatocellular carcinoma. <i>Journal of Pathology</i> , 2019, 248, 164-178.	2.1	82
110	Hepatocellular Carcinoma: Etiology and Current and Future Drugs. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 221-232.	0.4	167
111	An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice. <i>Hepatology</i> , 2019, 69, 2518-2532.	3.6	47
112	Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 1-11.	4.2	48
113	Success of immune checkpoint blockade therapies – mechanisms and implications for hepatology. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 74-86.	0.2	2
114	<p></p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4297-4312.	0.9	47
115	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 615-621.	1.4	5

#	ARTICLE	IF	CITATIONS
116	Systemic Treatment Options in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 427-446.	4.2	89
117	Injectable peptide hydrogel as intraperitoneal triptolide depot for the treatment of orthotopic hepatocellular carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 1050-1060.	5.7	23
118	Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2019, 6, HEP11.	4.2	24
119	Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. <i>Cells</i> , 2019, 8, 604.	1.8	12
120	Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. <i>Gut</i> , 2019, 68, 2019-2031.	6.1	230
121	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019, 30, 1448-1459.	0.6	146
122	Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. <i>Cancers</i> , 2019, 11, 841.	1.7	68
123	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. <i>Modern Pathology</i> , 2019, 32, 1646-1656.	2.9	16
124	Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma. <i>Journal of Pathology</i> , 2019, 249, 166-172.	2.1	26
125	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	1.8	180
126	Molecular and histological correlations in liver cancer. <i>Journal of Hepatology</i> , 2019, 71, 616-630.	1.8	308
127	Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. <i>Cancer</i> , 2019, 125, 3234-3241.	2.0	73
128	β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
129	Systemic Treatment for Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 341-358.	4.2	82
130	Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984346.	1.4	19
131	Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 71-84.	1.8	54
132	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 248-260.	1.8	8
133	Pembrolizumab for the Treatment of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 143-154.	4.2	25



#	ARTICLE	IF	CITATIONS
134	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. CardioVascular and Interventional Radiology, 2019, 42, 1262-1270.	0.9	2
135	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
136	Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report. Tohoku Journal of Experimental Medicine, 2019, 247, 247-250.	0.5	4
137	Immunotherapy in hepatocellular carcinoma. Annals of Hepatology, 2019, 18, 291-297.	0.6	66
138	Proteomics promises a new era of precision cancer medicine. Signal Transduction and Targeted Therapy, 2019, 4, 13.	7.1	4
139	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	3.4	526
140	Pharmacological treatment of hepatocellular carcinoma with cavoatrial tumor thrombus " case series and literature review. Zeitschrift Fur Gastroenterologie, 2019, 57, 501-507.	0.2	6
141	Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatology Research, 2019, 49, 1054-1065.	1.8	40
142	Implications of Immunotherapy in Hepatobiliary Tumors. Visceral Medicine, 2019, 35, 18-26.	0.5	6
143	New treatment-induced adverse effects we need to learn as modern hepatologists. Hepatology International, 2019, 13, 391-394.	1.9	0
144	Role of immune checkpoint inhibitors in gastrointestinal cancer treatment. Memo - Magazine of European Medical Oncology, 2019, 12, 71-76.	0.3	2
145	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Advances in Cancer Research, 2019, 143, 63-144.	1.9	52
146	Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut, 2019, 68, 1653-1666.	6.1	246
147	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.	1.3	28
148	<sc>MYC</sc> in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities. Immunological Reviews, 2019, 288, 178-197.	2.8	42
149	Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?. Digestive Diseases and Sciences, 2019, 64, 918-927.	1.1	26
150	Immunological and clinical implications of immune checkpoint blockade in human cancer. Archives of Pharmacal Research, 2019, 42, 567-581.	2.7	17
151	Progression after Immunotherapy for Fibrolamellar Carcinoma. Visceral Medicine, 2019, 35, 39-42.	0.5	19

#	ARTICLE	IF	CITATIONS
152	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. <i>Oncologist</i> , 2019, 24, S3-S10.	1.9	108
153	Immunotherapy: Current Status and Future Perspectives. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1030-1040.	1.1	24
154	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
155	Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. <i>World Journal of Gastroenterology</i> , 2019, 25, 789-807.	1.4	135
156	Role of CXCR6 in Antitumor Immune Surveillance. <i>Gastroenterology</i> , 2019, 156, 1565-1568.	0.6	1
157	RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. <i>Future Oncology</i> , 2019, 15, 1811-1822.	1.1	99
158	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 17-29.	2.6	45
159	Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1450-1462.	13.9	2,966
160	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	1.9	106
161	Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. <i>Hepatology</i> , 2019, 70, 1437-1442.	3.6	104
162	Has PD-1 MET Its Match in Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2019, 156, 1563-1565.	0.6	1
163	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. <i>Journal of Hepatology</i> , 2019, 70, 1262-1277.	1.8	150
164	A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1984-1991.	1.4	7
165	Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 343-353.	1.1	16
166	The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. <i>Targeted Oncology</i> , 2019, 14, 115-123.	1.7	19
167	Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 31-39.	1.8	55
168	Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 19.	1.3	34
169	Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. <i>Surgical Oncology</i> , 2019, 28, 228-235.	0.8	23

#	ARTICLE	IF	CITATIONS
170	Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?. Seminars in Nuclear Medicine, 2019, 49, 170-181.	2.5	8
171	Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visceral Medicine, 2019, 35, 43-46.	0.5	6
172	Emerging Role of the Pathologist in Precision Medicine for HCC. Digestive Diseases and Sciences, 2019, 64, 928-933.	1.1	5
173	Supplementary Sorafenib Therapies for Hepatocellular Carcinoma—A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology, 2019, 53, 486-494.	1.1	6
175	Predictive and prognostic implications of microsatellite instability and mismatch repair deficiency in carcinomas of the gastrointestinal tract, liver, and pancreas. Precision Cancer Medicine, 2019, 2, 36-36.	1.8	1
176	Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 2055-2066.	2.0	94
177	Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2019, 28, 717-729.	0.6	9
178	Systemic Therapy for Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 695-715.	0.6	9
179	Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomedical Journal, 2019, 42, 299-306.	1.4	62
180	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
181	Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333.		129
182	The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma. Current Hepatology Reports, 2019, 18, 371-382.	0.4	0
183	Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. , 2019, 7, 322.		122
184	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707.	7.7	157
185	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer, 2019, 8, 413-426.	4.2	40
186	A Phase 2 Study of Galunisertib (TGF-Î²1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2019, 10, e00056.	1.3	151
187	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926.	1.7	27
188	The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. Journal of Oncology, 2019, 2019, 1-22.	0.6	10

#	ARTICLE	IF	CITATIONS
189	<p>Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10335-10342.	1.0	19
190	Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00058.	1.3	38
191	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , 2019, 69, 2048-2060.	3.6	77
192	Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 510-524.	0.6	179
193	Sorafenib: key lessons from over 10 years of experience. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 177-189.	1.1	72
194	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. <i>European Journal of Cancer</i> , 2019, 106, 1-11.	1.3	37
195	Liver damage related to immune checkpoint inhibitors. <i>Hepatology International</i> , 2019, 13, 248-252.	1.9	36
196	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. <i>Future Oncology</i> , 2019, 15, 563-565.	1.1	2
197	Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. <i>Current Treatment Options in Oncology</i> , 2019, 20, 3.	1.3	26
198	Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. <i>Clinical Cancer Research</i> , 2019, 25, 515-523.	3.2	354
199	Medical oncologists must get more involved in systemic treatment. <i>Annals of Oncology</i> , 2019, 30, 6-8.	0.6	2
200	Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. <i>Clinical and Translational Oncology</i> , 2019, 21, 702-712.	1.2	38
201	New Systemic Treatments in Advanced Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2019, 25, 311-322.	1.3	21
202	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 567-572.	1.2	44
203	Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 365-379.	6.1	117
204	Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 25-34.	0.2	72
205	2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 43-80.	0.4	47
206	Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. <i>Pharmacoeconomics</i> , 2020, 38, 5-24.	1.7	13

#	ARTICLE	IF	CITATIONS
208	The Major Histocompatibility Complex Class II-CD4 Immunologic Synapse in Alcoholic Hepatitis and Autoimmune Liver Pathology. <i>American Journal of Pathology</i> , 2020, 190, 25-32.	1.9	9
209	Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 1247-1261.	3.6	247
210	4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 955-971.	3.6	70
211	The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. <i>Journal of Hepatology</i> , 2020, 72, 167-182.	1.8	116
212	Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 15-26.	2.3	115
213	REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. <i>Journal of Gastroenterology</i> , 2020, 55, 113-122.	2.3	123
214	Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 8-8.	1.5	18
215	Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2020, 11, 557-565.	0.5	5
216	Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. <i>Journal of Hepatology</i> , 2020, 72, 725-735.	1.8	71
217	When food regimes become hegemonic: Agrarian India through a Gramscian lens. <i>Journal of Agrarian Change</i> , 2020, 20, 188-206.	0.8	8
218	Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 489-497.	1.8	38
219	Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 384-396.	1.9	18
220	Developments in predictive biomarkers for hepatocellular carcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 63-74.	1.1	14
221	Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. <i>Pathology International</i> , 2020, 70, 140-154.	0.6	7
222	XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti-PD-1 Efficacy. <i>Cancer Immunology Research</i> , 2020, 8, 81-93.	1.6	34
223	TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. <i>Hepatology</i> , 2020, 72, 923-939.	3.6	36
224	Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. <i>Frontiers of Medicine</i> , 2020, 14, 273-283.	1.5	9
225	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. <i>Cancer Letters</i> , 2020, 473, 25-32.	3.2	40

#	ARTICLE	IF	CITATIONS
226	Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with $\hat{\pm}$ -fetoprotein concentrations of at least 400 $\hat{\mu}$ g/ml. <i>Journal of Medical Economics</i> , 2020, 23, 347-352.	1.0	12
227	Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 93-104.	4.2	60
228	Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. <i>Acta Radiologica</i> , 2020, 61, 983-991.	0.5	9
229	Harnessing big $\hat{\mu}$ omics $\hat{\mu}$ data and AI for drug discovery in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 238-251.	8.2	90
230	Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2020, 40, 131-142.	1.8	3
231	Current discovery strategies for hepatocellular carcinoma therapeutics. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 243-258.	2.5	15
232	Immunotherapy for hepatocellular carcinoma. <i>Cancer Letters</i> , 2020, 470, 8-17.	3.2	169
233	Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 1904-1906.	6.1	24
234	Review article: new therapeutic interventions for advanced hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 78-89.	1.9	71
235	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
236	Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2020, 82, 101946.	3.4	104
237	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	0.8	1,255
238	The chances of hepatic resection curing hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 711-717.	1.8	41
239	A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC). <i>Hpb</i> , 2020, 22, 649-659.	0.1	15
240	Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. <i>Frontiers in Immunology</i> , 2020, 11, 568759.	2.2	79
241	Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. <i>Cancers</i> , 2020, 12, 2859.	1.7	92
242	Downstaging to Liver Transplant. <i>Clinics in Liver Disease</i> , 2020, 24, 665-679.	1.0	0
243	The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188451.	3.3	36

#	ARTICLE	IF	CITATIONS
244	The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110797.	2.5	35
245	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 755-769.	1.0	9
246	Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 567950.	1.6	13
247	Therapy of Primary Liver Cancer. <i>Innovation(China)</i> , 2020, 1, 100032.	5.2	46
248	Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094748.	0.8	3
249	Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2730.	1.7	24
250	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	1.7	12
251	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
252	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. <i>Frontiers in Oncology</i> , 2020, 10, 563249.	1.3	18
253	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. <i>Cancers</i> , 2020, 12, 3025.	1.7	55
254	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
255	Role of External Beam Radiotherapy in Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 701-717.	1.0	11
256	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
257	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612.	4.2	10
258	Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. <i>Vaccines</i> , 2020, 8, 616.	2.1	47
259	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	3.4	124
260	Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 1813-1823.	0.9	0
261	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21

#	ARTICLE	IF	CITATIONS
262	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. Vaccines, 2020, 8, 578.	2.1	16
263	Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. International Journal of Molecular Sciences, 2020, 21, 7268.	1.8	33
264	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Reports, 2020, 2, 100170.	2.6	86
265	Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1632.	1.3	5
266	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. JAMA Oncology, 2020, 6, e204564.	3.4	746
267	Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?. Clinical Liver Disease, 2020, 16, 96-100.	1.0	0
268	Immunotherapy for advanced hepatocellular carcinoma, where are we?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188441.	3.3	52
269	Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. Scandinavian Journal of Gastroenterology, 2020, 55, 1057-1062.	0.6	15
270	Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. Journal of Oncology, 2020, 2020, 1-4.	0.6	1
271	Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. Liver Cancer, 2020, 9, 326-337.	4.2	11
272	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	1.7	47
273	Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs, 2020, 80, 1203-1210.	4.9	21
274	Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report. Anticancer Research, 2020, 40, 4123-4129.	0.5	9
275	Immunotherapy in Gastrointestinal Cancers. Visceral Medicine, 2020, 36, 231-237.	0.5	7
276	Novel systemic therapy for hepatocellular carcinoma. Hepatology International, 2020, 14, 638-651.	1.9	15
277	Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Frontiers in Oncology, 2020, 10, 600233.	1.3	10
278	&lt;p&gt;Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 11725-11740.	1.0	25
279	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87



#	ARTICLE	IF	CITATIONS
280	Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 937-947.	2.3	155
281	Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2020, 21, 1097-1104.	1.5	7
282	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. <i>Frontiers in Oncology</i> , 2020, 10, 590058.	1.3	5
283	A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1253-1253.	0.7	3
284	High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39 <sup>+</sup> CD8 <sup>+</sup> T cells. <i>Gut</i> , 2021, 70, 1965-1977.	6.1	72
285	Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12477-12487.	1.0	9
286	Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 289-299.	1.8	25
287	Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. <i>Frontiers in Oncology</i> , 2020, 10, 580241.	1.3	31
288	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
289	Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma. <i>Cell and Bioscience</i> , 2020, 10, 127.	2.1	51
290	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	0.8	350
291	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3397.	1.7	17
292	Current perspectives on the tumor microenvironment in hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 947-957.	1.9	46
293	Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. <i>Journal of Clinical Medicine</i> , 2020, 9, 2533.	1.0	15
294	Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8 <sup>+</sup> T cells in hepatocellular carcinoma using multiplex quantitative analysis. <i>Journal of Translational Medicine</i> , 2020, 18, 306.	1.8	88
295	The clinical application of camrelizumab on advanced hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 1017-1024.	1.4	14
296	2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 452-463.	0.7	267
297	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	3.0	37

#	ARTICLE	IF	CITATIONS
298	Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 693-695.	13.9	16
299	Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. <i>Cancers</i> , 2020, 12, 1968.	1.7	40
300	Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5232.	1.8	7
301	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093761.	1.4	78
302	A new clinical prognostic nomogram for liver cancer based on immune score. <i>PLoS ONE</i> , 2020, 15, e0236622.	1.1	7
303	The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. <i>Frontiers in Immunology</i> , 2020, 11, 1680.	2.2	194
304	Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. <i>Cancers</i> , 2020, 12, 2045.	1.7	12
305	Image-Guided Interventions in Oncology. , 2020, , .		1
306	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , 2020, 12, 2132.	1.7	18
307	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2960-2970.	0.8	723
308	Immuno-oncology for esophageal cancer. <i>Future Oncology</i> , 2020, 16, 2673-2681.	1.1	16
309	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
310	Efficacy and Safety of Banxia XieXin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients With Advanced Hepatocellular Carcinoma. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542094258.	0.8	8
311	Targeted therapy for hepatocellular carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 146.	7.1	320
312	Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
313	Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. <i>Annals of Translational Medicine</i> , 2020, 8, 1187-1187.	0.7	31
314	PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. <i>Frontiers in Immunology</i> , 2020, 11, 589997.	2.2	45
315	Novel Therapies for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3049.	1.7	2

#	ARTICLE	IF	CITATIONS
316	New advances in the diagnosis and management of hepatocellular carcinoma. <i>BMJ, The</i> , 2020, 371, m3544.	3.0	210
317	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 3048.	1.7	37
318	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
319	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072.		45
320	Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6302.	1.8	16
321	Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e249-e261.	0.7	18
322	Liquid biopsy in the clinical management of hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 2025-2034.	6.1	77
323	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6350-6361.	3.2	35
324	Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. <i>Cells</i> , 2020, 9, 1985.	1.8	7
325	Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. <i>Scientific Reports</i> , 2020, 10, 14470.	1.6	11
326	Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. <i>Liver Cancer</i> , 2020, 9, 549-562.	4.2	14
327	Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2020, 13, 911-922.	0.7	20
328	New Therapeutic Options for Advanced Hepatocellular Carcinoma. <i>Cancer Control</i> , 2020, 27, 107327482094597.	0.7	15
329	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. <i>Cancer Medicine</i> , 2020, 9, 7453-7459.	1.3	11
330	Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1233-1241.	0.2	11
331	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70
332	Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 7440-7452.	1.3	24
333	Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 116.	1.8	9

#	ARTICLE	IF	CITATIONS
334	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020, 5, e000714.	2.0	51
335	&lt;p&gt;Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 133-142.	1.8	29
338	Hepatocellular Carcinoma&acirc;“Circulating Tumor Cells Expressing PD&acirc;L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. <i>Hepatology Communications</i> , 2020, 4, 1527-1540.	2.0	60
339	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2495.	1.7	12
340	&lt;p&gt;Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3625-3649.	2.0	80
341	Bromo&acirc;and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 3503-3515.	1.7	17
342	Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094877.	1.4	45
343	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. <i>Current HIV/AIDS Reports</i> , 2020, 17, 547-556.	1.1	21
344	Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. <i>American Journal of Gastroenterology</i> , 2020, 115, 1960-1969.	0.2	11
345	&lt;p&gt;Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12683-12693.	1.0	26
346	Therapy in Advanced Hepatocellular Carcinoma. <i>Seminars in Interventional Radiology</i> , 2020, 37, 466-474.	0.3	11
347	Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492096877.	0.6	1
348	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3830.	1.7	47
349	Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. <i>Current Oncology</i> , 2020, 27, 152-164.	0.9	14
350	Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. <i>Annals of Translational Medicine</i> , 2020, 8, 1530-1530.	0.7	0
351	Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. <i>Liver Research</i> , 2020, 4, 191-198.	0.5	8
352	Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. <i>Liver Research</i> , 2020, 4, 180-190.	0.5	6
353	Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. <i>Cancer Communications</i> , 2020, 40, 681-693.	3.7	40

#	ARTICLE	IF	CITATIONS
354	CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5 and LSD1 in NF- $\kappa$ B oncogenic signaling. <i>Clinical and Translational Medicine</i> , 2020, 10, e233.	1.7	51
356	&lt;p&gt;Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 337-345.	1.8	6
357	TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 575776.	1.1	15
358	Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	16
359	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
360	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
361	Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. <i>Liver Cancer</i> , 2020, 9, 663-681.	4.2	27
362	Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 629-639.	4.2	20
363	Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 747-755.	1.0	15
364	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 568931.	2.2	100
365	New systemic agents for hepatocellular carcinoma: an update 2020. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 177-183.	1.0	17
366	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP- $\beta$ , in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3936-3946.	3.2	86
367	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. <i>Drug Resistance Updates</i> , 2020, 51, 100702.	6.5	53
368	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1221.	1.7	46
369	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020, 9, 245-260.	4.2	172
370	Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. <i>Molecular Cancer</i> , 2020, 19, 92.	7.9	147
371	Navigating the new landscape of secondâ€line treatment in advanced hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 1800-1811.	1.9	33
372	Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. <i>Clinical Cancer Research</i> , 2020, 26, 3979-3989.	3.2	184

#	ARTICLE	IF	CITATIONS
373	Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
374	FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 586.	1.3	42
375	Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019. <i>Hematological Oncology</i> , 2020, 38, 565-575.	0.8	22
376	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. <i>Journal of Hematology and Oncology</i> , 2020, 13, 47.	6.9	84
377	Atezolizumab plus Bevacizumab – A Landmark in Liver Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1953-1955.	13.9	44
378	Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 808-820.	5.1	371
379	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	13.9	3,828
380	Cabozantinib as a second-line treatment option in hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 623-629.	1.3	8
381	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
382	Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2020, 9, 10.	2.0	48
383	ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. , 2020, 8, e000340.		124
384	Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. <i>Frontiers in Immunology</i> , 2020, 11, 1037.	2.2	55
385	Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells. <i>Nano Letters</i> , 2020, 20, 5133-5140.	4.5	19
386	The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas. <i>Clinical Cancer Research</i> , 2020, 26, 4947-4957.	3.2	24
387	Is the era of sorafenib over? A review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092760.	1.4	45
388	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. <i>Future Oncology</i> , 2020, 16, 1525-1536.	1.1	50
389	Ulcerative esophagitis associated with combined nivolumab and ipilimumab therapy. <i>Journal of Dermatology</i> , 2020, 47, e299-e300.	0.6	7
390	Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. <i>Cells</i> , 2020, 9, 1370.	1.8	256

#	ARTICLE	IF	CITATIONS
391	Finding the hot spot: identifying immune sensitive gastrointestinal tumors. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 48-48.	1.5	6
392	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. <i>Gene Expression</i> , 2020, 20, 53-65.	0.5	65
393	Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. , 2020, 8, e000665.		8
394	Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. <i>Lung Cancer</i> , 2020, 146, 145-153.	0.9	14
395	Advances in immunotherapy for colorectal cancer: a review. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482091752.	1.4	139
396	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
397	Cautious Optimismâ€”The Current Role of Immunotherapy in Gastrointestinal Cancers. <i>Current Oncology</i> , 2020, 27, 59-68.	0.9	4
398	Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. <i>Oncologist</i> , 2020, 25, e946-e954.	1.9	3
399	Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 348-349.	0.7	1
400	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	2.6	154
401	Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. <i>Genes and Diseases</i> , 2020, 7, 359-369.	1.5	40
402	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 21-21.	1.5	2
403	N6-methyladenosine (m6A) RNA methylation regulators are associated with clinical prognosis in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 323-334.	0.4	2
404	Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. <i>Genes and Diseases</i> , 2020, 7, 320-327.	1.5	10
405	The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 174-185.	1.8	13
406	Systemic therapy in advanced-stage hepatocellular carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 212-217.	0.3	1
407	Recent Advances in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 775.	1.7	70
408	Nivolumab for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 687-693.	1.4	30

#	ARTICLE	IF	CITATIONS
409	Establishment of a Prognostic Model Using Immune-Related Genes in Patients With Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 55.	1.1	14
410	Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 4298-4311.	1.6	27
411	Management of hepatitis B in the era of checkpoint inhibition. , 2020, 8, e000276.		2
412	Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 86-88.	0.7	1
413	Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2020, 4, 1073-1086.	2.0	28
414	<p>Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 91-99.	1.8	7
415	Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. <i>Frontiers in Oncology</i> , 2020, 10, 1043.	1.3	29
416	Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study. <i>Lung Cancer</i> , 2020, 147, 21-25.	0.9	10
417	Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093518.	1.4	6
418	Favorable outcomes of surgical resection for extrahepatic recurrent hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 978-984.	1.8	7
419	Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1663.	1.7	112
420	Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. <i>Cancers</i> , 2020, 12, 1668.	1.7	54
421	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
422	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , 2020, 7, HEP20.	4.2	30
423	Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188391.	3.3	96
424	Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2587-2595.	0.9	4
425	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104
426	Pembrolizumab for the treatment of esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1143-1150.	1.4	14



#	ARTICLE	IF	CITATIONS
428	<p><p>Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World<p>. OncoTargets and Therapy, 2020, Volume 13, 143-149.	1.0	15
429	The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP17.	4.2	46
430	Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response. Pharmaceuticals, 2020, 13, 26.	1.7	1
431	A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. British Journal of Cancer, 2020, 122, 963-970.	2.9	17
432	DC-CIK as a widely applicable cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 601-607.	1.4	28
433	Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 571-580.	5.1	373
434	Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. Lancet Oncology, The, 2020, 21, 479-481.	5.1	29
435	Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma. Scientific Reports, 2020, 10, 3392.	1.6	46
436	<p><p>The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma<p>. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 11-17.	1.8	64
437	Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Science Reports, 2020, 3, e147.	0.6	4
438	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transplantation, 2020, 26, 823-831.	1.3	25
439	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS&Ecirc;ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Annals of Oncology, 2020, 31, 334-351.	0.6	138
440	Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma. Cancer Letters, 2020, 476, 120-128.	3.2	17
441	Normalization Cancer Immunotherapy for Melanoma. Journal of Investigative Dermatology, 2020, 140, 1134-1142.	0.3	13
442	Current status of immunotherapy in gastrointestinal malignancies. Zeitschrift Fur Gastroenterologie, 2020, 58, 542-555.	0.2	5
444	Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine, 2020, 53, 102659.	2.7	48
445	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer, 2020, 145, 181-185.	0.9	36
446	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	1.8	310

#	ARTICLE	IF	CITATIONS
447	Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. <i>Biomolecules</i> , 2020, 10, 117.	1.8	39
448	Hepatocellular Carcinoma—How to Determine Therapeutic Options. <i>Hepatology Communications</i> , 2020, 4, 342-354.	2.0	14
449	Advances in molecular classification and precision oncology in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 215-229.	1.8	311
450	mRECIST for HCC: Performance and novel refinements. <i>Journal of Hepatology</i> , 2020, 72, 288-306.	1.8	292
451	Novel patient-derived preclinical models of liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 239-249.	1.8	41
452	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	1.8	165
453	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	1.8	39
454	Molecular therapies for HCC: Looking outside the box. <i>Journal of Hepatology</i> , 2020, 72, 342-352.	1.8	250
455	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	1.7	74
456	Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer. <i>Medicine (United States)</i> , 2020, 99, e19013.	0.4	64
457	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020, 15, 115-126.	1.7	15
458	Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. <i>Liver Cancer</i> , 2020, 9, 426-439.	4.2	26
459	Emerging biomarkers in HCC patients: Current status. <i>International Journal of Surgery</i> , 2020, 82, 70-76.	1.1	36
460	Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1089.	1.7	119
461	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. <i>Future Oncology</i> , 2020, 16, 975-989.	1.1	136
462	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
463	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. <i>Oncologist</i> , 2020, 25, e1280-e1285.	1.9	14
464	Immunotherapy in hepatocellular carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 218-222.	0.3	1

#	ARTICLE	IF	CITATIONS
465	The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. <i>Cancer Treatment Reviews</i> , 2020, 86, 102011.	3.4	31
466	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. <i>Frontiers in Immunology</i> , 2020, 11, 508.	2.2	58
467	Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5276-5286.	3.2	13
468	Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2020, 15, 53-58.	1.0	23
469	Necroptosis in Cholangiocarcinoma. <i>Cells</i> , 2020, 9, 982.	1.8	13
470	Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1175-1181.	0.9	12
471	Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 230-230.	0.7	15
472	Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 845-854.	0.7	2
473	Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. , 2020, 8, e000394.		39
474	A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. <i>Liver Cancer</i> , 2020, 9, 119-137.	4.2	45
475	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	6.9	146
476	Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2286.	1.8	61
477	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37.	3.0	17
478	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 583-590.	0.5	7
479	Systemic therapy for advanced hepatocellular carcinoma: targeted therapies. <i>Chinese Clinical Oncology</i> , 2021, 10, 10-10.	0.4	10
480	Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study. <i>Tumori</i> , 2021, 107, 32-38.	0.6	4
481	Evolution of Systemic Therapy for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 150-157.	3.6	70
482	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. <i>Visceral Medicine</i> , 2021, 37, 87-93.	0.5	6

#	ARTICLE	IF	CITATIONS
483	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
484	The Tumor Microenvironment in Cholangiocarcinoma Progression. <i>Hepatology</i> , 2021, 73, 75-85.	3.6	100
485	Liver Cancer Immunity. <i>Hepatology</i> , 2021, 73, 86-103.	3.6	52
486	Biomarkers for Hepatobiliary Cancers. <i>Hepatology</i> , 2021, 73, 115-127.	3.6	104
487	Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome. <i>Case Reports in Oncology</i> , 2021, 13, 1252-1257.	0.3	8
488	FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1836-1841.	3.2	102
489	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359.	1.8	122
490	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. <i>Gut</i> , 2021, 70, 204-214.	6.1	150
491	Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. <i>Hepatology</i> , 2021, 73, 821-832.	3.6	25
492	Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. <i>Hepatology</i> , 2021, 73, 104-114.	3.6	54
493	Transcriptome Profiling Identifies TIGIT as a Marker of T Cell Exhaustion in Liver Cancer. <i>Hepatology</i> , 2021, 73, 1399-1418.	3.6	61
494	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <i>Modern Pathology</i> , 2021, 34, 823-833.	2.9	6
495	Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1003-1011.	3.2	334
496	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 113.	3.4	213
497	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	2.6	77
498	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	3.2	27
499	Hepatitis C virus associated hepatocellular carcinoma. <i>Advances in Cancer Research</i> , 2021, 149, 103-142.	1.9	18
500	Systemic treatment of HCC in special populations. <i>Journal of Hepatology</i> , 2021, 74, 931-943.	1.8	72

#	ARTICLE	IF	CITATIONS
501	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. <i>Journal of Hepatology</i> , 2021, 74, 700-715.	1.8	60
502	Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 62-75.	1.4	7
503	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103167.	2.0	30
504	Hepatocellular carcinoma: Clinicopathologic associations amidst marked phenotypic heterogeneity. <i>Pathology Research and Practice</i> , 2021, 217, 153290.	1.0	2
505	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 112-127.	4.8	159
506	A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103173.	2.0	12
507	Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 423-433.	1.2	1
508	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	1.9	13
509	Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 187-202.	0.5	9
510	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103160.	2.0	26
511	Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	2.0	20
512	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1051-1060.	0.8	72
513	Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 739-762.	2.3	29
514	The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. <i>Oncologist</i> , 2021, 26, e1036-e1049.	1.9	30
515	Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. <i>Histopathology</i> , 2021, 79, 36-46.	1.6	49
516	Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. <i>Cell</i> , 2021, 184, 404-421.e16.	13.5	399
517	Aggressive surgical approach in patients with adrenal-only metastases from hepatocellular carcinoma enables higher survival rates than standard systemic therapy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 28-33.	0.6	5
518	Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 192-203.	1.9	32

#	ARTICLE	IF	CITATIONS
519	Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2021, 113, 123-136.	3.0	28
520	Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. <i>Liver Transplantation</i> , 2021, 27, 444-449.	1.3	24
521	Recurrence of hepatocellular carcinoma following liver transplantation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 91-102.	1.4	21
522	Gut microbiota: impacts on gastrointestinal cancer immunotherapy. <i>Gut Microbes</i> , 2021, 13, 1-21.	4.3	33
523	Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. <i>Theranostics</i> , 2021, 11, 5955-5969.	4.6	23
524	TIGIT and PD1 Co-blockade Restores ex Vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 443-464.	2.3	43
525	Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1929-1937.	2.0	19
526	The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 757-764.	0.9	0
527	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. <i>Pharmaceuticals</i> , 2021, 14, 36.	1.7	30
528	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	4.2	25
529	Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	1.4	10
530	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	1.4	15
531	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1499-1510.	0.7	3
532	Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2033761.	2.8	27
533	Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 227.	5.8	76
534	Systemic therapy of liver cancer. <i>Advances in Cancer Research</i> , 2021, 149, 257-294.	1.9	44
535	Experience with regorafenib in the treatment of hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110169.	1.4	74
536	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110311.	1.4	19

#	ARTICLE	IF	CITATIONS
537	Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 3969-3993.	1.4	7
538	Immunotherapy in hepatocellular cancer. <i>Advances in Cancer Research</i> , 2021, 149, 295-320.	1.9	0
539	Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 574778.	1.3	4
540	Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. <i>Frontiers in Immunology</i> , 2020, 11, 613946.	2.2	40
541	Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 1958-1966.	1.0	6
542	Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 144-156.	4.5	19
543	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110027.	1.4	91
544	ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	1.4	7
545	Perspectives of Radiotherapy in Immuno-oncology Era. , 2021, , 325-337.		0
546	Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 132-139.	1.2	19
547	Fundamentals of Digestive Cancers Immunology, Especially Gastric and Hepatocellular Carcinomas <i>Fondamentaux de l'immunologie des Cancers Digestifs (Gastriques et Hépatocellulaires)</i> . <i>Oncologie</i> , 2021, 23, 47-59.	0.2	5
548	Advanced drug delivery systems in liver cancer. , 2021, , 217-223.		1
549	Molecular Carcinogenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma. , 2021, , 123-141.		0
550	Image-Guided Intratumoral Delivery of Immunotherapeutics in Gastrointestinal Malignancies. <i>Digestive Disease Interventions</i> , 2021, 05, 022-031.	0.3	4
551	Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110381.	0.8	2
552	The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 238.	1.7	14
553	<i>LRP1B</i> or <i>TP53</i> mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2021, 12, 217-223.	1.2	30
554	A novel prognostic prediction model based on seven immune-related RNAs for predicting overall survival of patients in early cervical squamous cell carcinoma. <i>BMC Medical Genomics</i> , 2021, 14, 49.	0.7	7

#	ARTICLE	IF	CITATIONS
555	Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, e266-e277.	1.4	12
556	Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 618206.	1.3	53
557	The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2021, 16, 153-163.	1.7	5
558	Targeting tumor-associated macrophages to synergize tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 75.	7.1	323
559	Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma (Review). <i>Oncology Letters</i> , 2021, 21, 279.	0.8	36
560	Immunotherapy for hepatocellular carcinoma: The challenge of biomarker studies. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 121-122.	0.6	2
561	Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. <i>Current Hepatology Reports</i> , 2021, 20, 23-33.	0.4	10
562	The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1931.	1.8	31
563	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
564	Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. <i>Cancers</i> , 2021, 13, 584.	1.7	6
565	Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. <i>Cancer Cell International</i> , 2021, 21, 98.	1.8	46
566	PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	51
567	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	1.2	20
568	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945.		74
569	First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Cancers</i> , 2021, 13, 931.	1.7	26
570	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	1.7	7
571	Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution?. <i>JCO Oncology Practice</i> , 2021, 17, 164-166.	1.4	3
572	Understanding relevant immune mechanisms in gastrointestinal oncology. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522199286.	0.5	0



#	ARTICLE	IF	CITATIONS
573	Cellular heterogeneity and plasticity in liver cancer. <i>Seminars in Cancer Biology</i> , 2022, 82, 134-149.	4.3	58
574	The Roles of circRNAs in Liver Cancer Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 598464.	1.3	13
575	Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation. <i>Npj Precision Oncology</i> , 2021, 5, 27.	2.3	11
576	Emerging Role of Immune Therapy in HCC. <i>Digestive Disease Interventions</i> , 2021, 05, 277-282.	0.3	0
577	Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 1455.	5.8	96
578	Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 650481.	1.3	23
579	A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	43
580	Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 652172.	2.2	21
581	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
582	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCG, GERCOR, UNICANCER, SFGC, SFED, SFRO, AFEF, SIAD, SFR/FRI). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101590.	0.7	17
583	Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 602227.	1.6	3
584	Development and validation of a robust immune-related risk signature for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e24683.	0.4	7
585	Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 655697.	2.2	126
586	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
587	Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
588	CD8+ T Cell Responses during HCV Infection and HCC. <i>Journal of Clinical Medicine</i> , 2021, 10, 991.	1.0	22
589	Programmed cell death ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2601-2609.	1.4	5
590	Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 652007.	2.2	7

#	ARTICLE	IF	CITATIONS
591	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
592	The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 626984.	1.3	12
593	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.3	7
594	Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection. <i>Oncologist</i> , 2021, 26, e827-e830.	1.9	9
595	Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports. <i>Journal of Medical Case Reports</i> , 2021, 15, 132.	0.4	7
596	Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 589-598.	1.4	17
597	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. <i>Radiotherapy and Oncology</i> , 2021, 156, 120-126.	0.3	19
598	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. <i>AAPS Journal</i> , 2021, 23, 39.	2.2	356
599	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 301.	1.1	42
600	Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 287-289.	1.9	2
601	How to Treat Hepatocellular Carcinoma in Elderly Patients. <i>Pharmaceuticals</i> , 2021, 14, 233.	1.7	9
602	Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
603	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 177-191.	1.8	9
604	Immune Checkpoint Inhibitors in the Treatment of Cancer. <i>Current Clinical Pharmacology</i> , 2022, 17, 103-113.	0.2	18
605	Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. <i>Aging</i> , 2021, 13, 11257-11280.	1.4	11
606	Predictive Factors for the Effectiveness of Repeated Lines of Transarterial Chemoembolization in the Treatment of Localized Hepatocellular Carcinoma. <i>Journal of Oncology Diagnostic Radiology and Radiotherapy</i> , 2021, 4, 42-52.	0.1	0
607	Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021, 125, 190-199.	2.9	26
608	Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 635243.	1.6	22

#	ARTICLE	IF	CITATIONS
609	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. <i>BMC Cancer</i> , 2021, 21, 425.	1.1	16
610	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38
611	Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. <i>Cancers</i> , 2021, 13, 1729.	1.7	14
612	Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma. <i>Molecular Medicine</i> , 2021, 27, 36.	1.9	7
613	Immunotherapy Updates in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2164.	1.7	14
614	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 180-192.	0.7	47
615	Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. <i>Liver Cancer</i> , 2021, 10, 249-259.	4.2	49
616	Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. <i>Liver Cancer</i> , 2021, 10, 296-308.	4.2	63
617	miR-4456/CCL3/CCR5 Pathway in the Pathogenesis of Tight Junction Impairment in Chronic Obstructive Pulmonary Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 551839.	1.6	6
618	Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting. <i>Current Drug Targets</i> , 2021, 22, 779-792.	1.0	13
619	Advances in immunotherapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 525-543.	8.2	609
620	β-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy. <i>Cancers</i> , 2021, 13, 1830.	1.7	16
621	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. <i>Frontiers in Immunology</i> , 2021, 12, 643310.	2.2	27
622	Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 14, 119.	0.4	1
623	Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3207-3216.	2.0	21
624	Downstaging treatment for patients with hepatocellular carcinoma before transplantation. <i>Transplantation Reviews</i> , 2021, 35, 100606.	1.2	6
625	The Current Landscape of Clinical Trials for Systemic Treatment of HCC. <i>Cancers</i> , 2021, 13, 1962.	1.7	40
626	NAFLD-Associated HCC: Progress and Opportunities. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 223-239.	1.8	33

#	ARTICLE	IF	CITATIONS
627	Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 642958.	2.2	12
628	AB4 inhibits Notch signaling and promotes cancer cell apoptosis in liver cancer. <i>Oncology Reports</i> , 2021, 45, .	1.2	1
629	Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. <i>Annals of Translational Medicine</i> , 2021, 9, 652-652.	0.7	22
630	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , 2021, 10, 275-284.	4.2	29
631	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. <i>Current Opinion in Oncology</i> , 2021, 33, 386-394.	1.1	13
632	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	59
633	Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 1922.	1.7	29
634	Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. <i>Oncologist</i> , 2021, 26, e1216-e1225.	1.9	26
635	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
636	The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study. <i>Cancers</i> , 2021, 13, 2002.	1.7	8
637	Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. <i>Cancers</i> , 2021, 13, 1949.	1.7	31
638	Combined Inhibition of TGF- $\beta$ 1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 1889.	1.0	25
639	Impact of the microbiome on tumor immunity. <i>Current Opinion in Immunology</i> , 2021, 69, 39-46.	2.4	9
640	Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Panminerva Medica</i> , 2021, , .	0.2	2
641	Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2021, 28, 3107-3146.	1.2	9
642	Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1873-1882.	2.0	20
644	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 172.	3.5	104
645	Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. <i>Frontiers in Oncology</i> , 2021, 11, 559161.	1.3	34

#	ARTICLE	IF	CITATIONS
646	Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. <i>Cancers</i> , 2021, 13, 2708.	1.7	19
647	Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. <i>Cells</i> , 2021, 10, 1332.	1.8	24
648	Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. <i>Frontiers in Oncology</i> , 2021, 11, 683341.	1.3	13
649	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021, 125, 200-208.	2.9	22
650	Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 569.	1.1	17
651	Kinetics of the neutrophilâ€ lymphocyte ratio during PDâ€1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2189-2199.	1.9	26
652	The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. <i>Vaccines</i> , 2021, 9, 532.	2.1	65
653	Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy. <i>Cancers</i> , 2021, 13, 2543.	1.7	4
654	Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 94, 107467.	1.7	18
655	Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 771-792.	0.5	1
656	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 477-492.	1.8	15
657	Immuneâ€related adverse events predict responses to <sc>PD</sc>â€1 blockade immunotherapy in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2021, 149, 959-966.	2.3	15
658	Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 387-401.	1.8	62
660	Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs. <i>Anticancer Research</i> , 2021, 41, 2569-2573.	0.5	2
661	Imaging of treatment response during systemic therapy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 3625-3633.	1.0	5
662	Tâ€cell mediated responses against alphaâ€fetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patientsâ€™ survival. <i>Liver Cancer International</i> , 2021, 2, 7-14.	0.2	0
663	The therapeutic landscape of hepatocellular carcinoma. <i>Med</i> , 2021, 2, 505-552.	2.2	20
664	Role of modern radiotherapy in managing patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 2434-2457.	1.4	18

#	ARTICLE	IF	CITATIONS
665	Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 705-711.	0.7	2
666	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	1.8	182
667	Systemic Therapy for Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021, 17, 337-340.	1.0	5
668	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0249426.	1.1	11
669	Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 686621.	1.3	28
670	The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. <i>Cancers</i> , 2021, 13, 2651.	1.7	18
671	Immunotherapy for GI Cancers. <i>Advances in Oncology</i> , 2021, 1, 283-295.	0.1	0
672	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	1.8	10
673	Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	4
674	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 650486.	2.2	26
675	Advances in systemic therapy for the first-line treatment of unresectable HCC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 621-628.	1.1	11
676	Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 25-38.	2.0	15
677	Histopathology of Gastrointestinal Immune-related Adverse Events. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, e15-e26.	2.1	7
678	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
679	Hepatocellular Carcinoma in Sub-Saharan Africa. <i>JCO Global Oncology</i> , 2021, 7, 756-766.	0.8	25
680	Cellular based treatment modalities for unresectable hepatocellular carcinoma. <i>World Journal of Clinical Oncology</i> , 2021, 12, 290-308.	0.9	4
681	Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 507-512.	1.8	8
682	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 346-359.	4.2	70

#	ARTICLE	IF	CITATIONS
683	The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101664.	0.7	9
684	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. <i>Liver Cancer</i> , 2021, 10, 181-223.	4.2	307
685	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
686	A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. <i>Liver Cancer</i> , 2021, 10, 500-509.	4.2	9
687	Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 827-835.	1.9	3
688	Exploring liver cancer biology through functional genetic screens. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 690-704.	8.2	31
689	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. <i>Drugs and Aging</i> , 2021, 38, 579-591.	1.3	5
690	Editorial: Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 698515.	1.3	0
691	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	1.9	5
692	Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. <i>Drug Discovery Today</i> , 2021, 26, 1539-1546.	3.2	18
693	Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. <i>Immunotherapy</i> , 2021, 13, 637-644.	1.0	63
694	Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. <i>Future Oncology</i> , 2021, 17, 2243-2256.	1.1	36
695	Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. <i>Current Oncology</i> , 2021, 28, 2150-2172.	0.9	9
696	Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?. <i>World Journal of Gastroenterology</i> , 2021, 27, 3429-3439.	1.4	4
697	Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2662.	1.0	13
698	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32
699	Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. <i>Clinical and Experimental Medicine</i> , 2022, 22, 65-74.	1.9	41
700	Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	12

#	ARTICLE	IF	CITATIONS
701	<sc>FDA</sc> Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Oncologist</i> , 2021, 26, 797-806.	1.9	61
702	An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. <i>Frontiers in Pharmacology</i> , 2021, 12, 707930.	1.6	12
703	Characterization of response to atezolizumab+Bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. <i>Cancer Medicine</i> , 2021, 10, 5437-5447.	1.3	29
704	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	0.6	91
705	The TGF- $\beta$ Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. <i>Cancers</i> , 2021, 13, 3248.	1.7	37
706	Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. <i>Seminars in Liver Disease</i> , 2021, 41, 263-276.	1.8	14
707	USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 201.	3.5	27
708	Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , 2021, 10, 1651.	1.8	13
709	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 371-378.	1.9	65
710	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. <i>World Journal of Gastroenterology</i> , 2021, 27, 2994-3009.	1.4	103
711	Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. <i>JCO Oncology Practice</i> , 2022, 18, 35-41.	1.4	12
712	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. <i>World Journal of Gastroenterology</i> , 2021, 27, 4104-4142.	1.4	15
713	Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. <i>World Journal of Clinical Cases</i> , 2021, 9, 5754-5768.	0.3	9
714	Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. <i>World Journal of Clinical Cases</i> , 2021, 9, 5988-5998.	0.3	2
715	Emerging Regulatory Mechanisms Involved in Liver Cancer Stem Cell Properties in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 691410.	1.8	13
716	Cabozantinib: An evolving therapy for hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2021, 98, 102221.	3.4	43
717	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. <i>Journal of Clinical Medicine</i> , 2021, 10, 3201.	1.0	13
718	Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). <i>Frontiers in Oncology</i> , 2021, 11, 684867.	1.3	35



#	ARTICLE	IF	CITATIONS
719	How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. <i>Cancers</i> , 2021, 13, 3536.	1.7	4
720	Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. <i>Current Oncology Reports</i> , 2021, 23, 100.	1.8	26
721	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	2.0	9
722	Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC. <i>JCO Oncology Practice</i> , 2021, , OP.21.00451.	1.4	0
723	Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1353-1365.	1.3	6
724	Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7800.	1.8	26
725	Recent advances in immunotherapy for hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 511-520.	0.6	29
726	The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1195-1210.	1.2	8
727	Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S361-S373.	0.6	66
728	Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 690151.	1.6	28
729	On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3758.	1.7	8
730	Evolution of systemic treatment for advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 643-653.	0.8	11
731	The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1909.	1.8	6
732	Current cancer therapies and their influence on glucose control. <i>World Journal of Diabetes</i> , 2021, 12, 1010-1025.	1.3	10
733	Advances of Targeted Therapy for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 719896.	1.3	23
734	Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2â€³ study. <i>Lancet Oncology</i> , The, 2021, 22, 977-990.	5.1	459
735	How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 833-836.	0.6	21
736	Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	4

#	ARTICLE	IF	CITATIONS
737	Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. <i>BMC Cancer</i> , 2021, 21, 775.	1.1	28
738	Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?. <i>Expert Opinion on Investigational Drugs</i> , 2021, , 1-3.	1.9	1
739	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 809-822.	1.8	17
740	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. <i>World Journal of Stem Cells</i> , 2021, 13, 795-824.	1.3	7
741	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. <i>Oncologist</i> , 2021, 26, e1786-e1799.	1.9	52
742	Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. <i>Cancer</i> , 2021, 127, 3782-3793.	2.0	82
743	Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. , 2021, 9, e003132.		17
744	Obatoclox, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade. <i>Translational Oncology</i> , 2021, 14, 101116.	1.7	8
745	Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3517-3534.	1.2	5
746	Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. <i>Journal of Interventional Medicine</i> , 2021, 4, 105-113.	0.2	7
747	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. <i>Cancers</i> , 2021, 13, 4334.	1.7	20
748	The State of Immunotherapy in Hepatobiliary Cancers. <i>Cells</i> , 2021, 10, 2096.	1.8	18
749	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 887-897.	1.8	17
750	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1245-1251.	1.4	75
751	Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2115-2125.	1.2	55
752	Using cell-free DNA for HCC surveillance and prognosis. <i>JHEP Reports</i> , 2021, 3, 100304.	2.6	27
753	Comprehensive Analyses of the Infiltrating Immune Cell Landscape and Its Clinical Significance in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 4695-4704.	0.8	7
754	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. <i>Clinical Drug Investigation</i> , 2021, 41, 795-808.	1.1	4

#	ARTICLE	IF	CITATIONS
755	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4387.	1.7	15
756	Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. <i>Biomarker Research</i> , 2021, 9, 64.	2.8	13
757	Changes in Wnt and TGF- $\beta$ 2 Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 639779.	1.8	27
758	Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 434-442.	0.7	28
759	Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 896-904.	2.3	13
760	Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. <i>JHEP Reports</i> , 2021, 3, 100318.	2.6	5
761	Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. <i>Frontiers in Oncology</i> , 2021, 11, 650394.	1.3	16
762	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 772-798.	0.8	11
763	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 147-158.	0.7	21
764	Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8602-8614.	1.6	15
765	Recent update on comprehensive therapy for advanced hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 845-855.	0.8	10
766	Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	4
767	Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 615-628.	4.2	31
768	A Molecular Hepatocellular Carcinoma Prognostic Score System Precisely Predicts Overall Survival of Hepatocellular Carcinoma Patients. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 273-283.	0.7	3
769	Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 712351.	2.2	5
770	Combined DNA Methylation and Transcriptomic Assessments to Determine a Prognostic Model for PD-1-Negative Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 708819.	1.8	4
771	KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 137, 106037.	1.2	3
772	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 927-939.	1.1	9

#	ARTICLE	IF	CITATIONS
773	Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1749.	3.3	15
774	Antitumor and off-target effects of cholesterol-conjugated let-7a mimics in an orthotopic hepatocellular carcinoma xenograft nude mouse model. <i>Journal of Bio-X Research</i> , 2021, Publish Ahead of Print, .	0.3	0
775	Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4343.	1.7	8
776	Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3879-3890.	1.6	21
777	Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. <i>British Journal of Cancer</i> , 2021, , .	2.9	12
778	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9044.	1.8	7
779	Application of Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 699060.	1.3	8
780	Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2022, 9, HEP41.	4.2	2
781	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 87.	1.3	25
782	PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 415-423.	1.9	78
783	A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1129-1145.	1.8	5
784	Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 720748.	2.2	5
786	Medical therapy of HCC. <i>Journal of Hepatology</i> , 2022, 76, 208-210.	1.8	11
787	Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. <i>Oncologist</i> , 2021, 26, e2227-e2238.	1.9	23
788	The effect of patient sex on the efficacy and safety of anticancer immunotherapy. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1535-1544.	1.0	10
789	Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma “The Changing Tides. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1089-1115.	1.8	28
790	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1132-1143.	0.8	2
791	An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously. <i>Journal of Hepatology</i> , 2021, , .	1.8	3

#	ARTICLE	IF	CITATIONS
792	The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110450.	0.5	3
793	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021, 13, 4882.	1.7	15
794	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1195-1207.	1.8	19
795	Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1063-1074.	2.0	26
796	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
797	Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1147-1158.	1.8	8
798	Heat Shock Protein Beta 1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5483-5492.	0.8	11
799	Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 730240.	1.8	7
800	Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment. <i>Medicine (United States)</i> , 2021, 100, e27013.	0.4	4
801	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002â€“2020). <i>Gastroenterology</i> , 2021, 161, 879-898.	0.6	123
802	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4719.	1.7	7
803	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 716844.	1.3	12
804	Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. <i>Seminars in Liver Disease</i> , 2022, 42, 087-103.	1.8	10
805	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , 2022, 76, 446-457.	1.8	121
806	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
807	Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. <i>OncoTargets and Therapy</i> . 2021. Volume 14. 4859-4865.	1.0	2
808	Paradigm shift in the treatment options of hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2067-2079.	1.9	19
809	Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. <i>Cancer Cell International</i> , 2021, 21, 503.	1.8	14

#	ARTICLE	IF	CITATIONS
810	Embracing cancer immunotherapy with vital micronutrients. World Journal of Clinical Oncology, 2021, 12, 712-724.	0.9	10
811	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Digestive and Liver Disease, 2021, , .	0.4	2
812	Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opinion on Therapeutic Targets, 2021, 25, 645-658.	1.5	5
813	Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 1700-1705.	0.4	1
814	Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review. Journal of International Medical Research, 2021, 49, 030006052110445.	0.4	2
815	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	0.8	257
816	Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Frontiers in Immunology, 2021, 12, 733530.	2.2	23
817	Systemic Therapy in Hepatocellular Carcinoma. , 0, , .		0
818	Epigenetic mechanisms of liver tumor resistance to immunotherapy. World Journal of Hepatology, 2021, 13, 979-1002.	0.8	5
819	Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 953-966.	0.8	4
820	The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Frontiers in Oncology, 2021, 11, 635731.	1.3	26
821	HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines, 2021, 9, 1345.	1.4	22
822	Systemic treatment of hepatocellular carcinoma: An EASL position paper. Journal of Hepatology, 2021, 75, 960-974.	1.8	217
823	Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surgery and Nutrition, 2021, 10, 661-671.	0.7	46
824	The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. International Journal of General Medicine, 2021, Volume 14, 6343-6358.	0.8	4
825	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. International Immunopharmacology, 2021, 100, 108128.	1.7	13
826	Controversies in the Management of Hepatitis B. Clinics in Liver Disease, 2021, 25, 785-803.	1.0	4
827	Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis. International Immunopharmacology, 2021, 100, 108135.	1.7	3

#	ARTICLE	IF	CITATIONS
828	TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 611444.	1.8	24
829	Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 609322.	1.6	48
830	The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 2415.	1.6	26
831	Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 343-352.	0.6	13
832	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 39-52.	1.0	9
833	Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma. , 2021, , 333-364.		0
834	Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. <i>Theranostics</i> , 2021, 11, 3489-3501.	4.6	35
835	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. <i>Liver Cancer</i> , 2021, 10, 380-393.	4.2	51
836	Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. <i>Liver Cancer</i> , 2021, 10, 137-150.	4.2	21
837	Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2775-2789.	1.9	22
838	Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. <i>Cancers</i> , 2021, 13, 192.	1.7	27
839	Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers. <i>Hepatoma Research</i> , 2021, 2021, .	0.6	14
840	Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma. , 2021, , 277-283.		0
841	Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. <i>Cancers</i> , 2021, 13, 213.	1.7	6
842	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. <i>Pharmaceuticals</i> , 2021, 14, 43.	1.7	8
843	Checkpoint Inhibitors and Hepatotoxicity. <i>Biomedicines</i> , 2021, 9, 101.	1.4	17
844	Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. <i>Korean Journal of Radiology</i> , 2021, 22, 1822-1833.	1.5	9
845	Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
846	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	18.1	2,757
847	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer, 2021, 10, 451-460.	4.2	5
848	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-CHCC. Hepatology Communications, 2021, 5, 538-547.	2.0	6
849	Molecular-Targeted Therapies in Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 225-238.	0.4	7
850	Immune Therapies. Molecular and Translational Medicine, 2019, , 239-253.	0.4	1
851	Stromal and Immune Drivers of Hepatocarcinogenesis. Molecular and Translational Medicine, 2019, , 317-331.	0.4	5
852	Spatiotemporal Changes in Checkpoint Molecule Expression. Advances in Experimental Medicine and Biology, 2020, 1248, 167-200.	0.8	5
853	Immunotherapies in clinical development for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 351-363.	1.9	28
854	Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. JNCI Cancer Spectrum, 2021, 5, pkaa100.	1.4	12
855	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 74-81.	0.6	36
856	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2021, 55, 263-270.	1.1	3
857	Transplant Oncology in Primary and Metastatic Liver Tumors. Annals of Surgery, 2021, 273, 483-493.	2.1	33
859	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
860	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020, 9, 682-720.	4.2	427
861	Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer, 2020, 9, 640-662.	4.2	78
862	Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. Journal of Clinical Investigation, 2020, 130, 4679-4693.	3.9	42
863	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2020, 38, 1081.	0.8	101
864	Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Research, 2020, 9, 620.	0.8	41



#	ARTICLE	IF	CITATIONS
865	Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?. <i>World Journal of Clinical Cases</i> , 2019, 7, 1253-1261.	0.3	13
866	Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-8.	0.7	41
867	Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 168-176.	0.7	49
868	Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2019, 19, 1-11.	0.3	4
869	Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2020, 20, 128-134.	0.3	6
870	New landscapes and horizons in hepatocellular carcinoma therapy. <i>Aging</i> , 2020, 12, 3053-3094.	1.4	37
871	Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications. <i>Aging</i> , 2020, 12, 4970-4995.	1.4	11
872	Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes. <i>Aging</i> , 2020, 12, 12187-12205.	1.4	13
873	Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 25172-25188.	1.4	5
874	Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. <i>Hepatoma Research</i> , 2020, 2020, .	0.6	6
875	Immune checkpoint inhibitor in liver cancer—unique regional differences. <i>Annals of Translational Medicine</i> , 2020, 8, 1336-1336.	0.7	4
876	Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure. <i>Annals of Translational Medicine</i> , 2020, 8, 1700-1700.	0.7	6
877	Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1614-1614.	0.7	2
878	Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2020, 27, 4789-4805.	1.2	6
879	A Case of Acute Exacerbation of Hepatitis B by Pembrolizumab for a Lung Adenocarcinoma Patient with Hepatitis B Surface Antigen. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 115-119.	0.0	2
880	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 155-162.	4.5	44
881	Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1274.	1.7	27
882	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6

#	ARTICLE	IF	CITATIONS
883	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 90.	1.7	21
884	Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 232.	1.8	6
885	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. <i>Pharmaceuticals</i> , 2021, 14, 3.	1.7	16
886	Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. <i>Pharmaceuticals</i> , 2021, 14, 28.	1.7	17
887	A Systematic Review and Network Meta-Analysis of Second-Line Therapy in Hepatocellular Carcinoma. <i>Current Oncology</i> , 2020, 27, 300-306.	0.9	7
888	Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond. <i>Current Oncology</i> , 2020, 27, 173-180.	0.9	5
889	Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. <i>World Journal of Gastroenterology</i> , 2019, 25, 3607-3618.	1.4	14
890	Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 3704-3721.	1.4	107
891	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 3870-3896.	1.4	70
892	Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. <i>World Journal of Gastroenterology</i> , 2020, 26, 1888-1900.	1.4	20
893	Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. <i>World Journal of Gastroenterology</i> , 2020, 26, 3720-3736.	1.4	32
894	Targeting cancer stem cells in cholangiocarcinoma (Review). <i>International Journal of Oncology</i> , 2020, 57, 397-408.	1.4	15
895	Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review). <i>Oncology Letters</i> , 2020, 20, 45.	0.8	12
896	Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. <i>Oncology Reviews</i> , 2020, 14, 515.	0.8	5
897	Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI). <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 327-334.	0.3	12
898	Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?. <i>Immune Network</i> , 2020, 20, e11.	1.6	42
899	Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 663-676.	0.8	13
900	Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?. <i>World Journal of Transplantation</i> , 2020, 10, 297-306.	0.6	8

#	ARTICLE	IF	CITATIONS
901	Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 669-675.	2.3	29
902	Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 302-310.	2.3	214
903	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 541-565.	2.3	477
904	Second-line treatment options in hepatocellular carcinoma. <i>Drugs in Context</i> , 2019, 8, 1-13.	1.0	32
905	The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. <i>Advances in Clinical Medicine</i> , 2021, 11, 4628-4634.	0.0	0
906	Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S272-2S279.	0.0	0
907	Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. <i>Immunotherapy</i> , 2021, 13, 1395-1405.	1.0	35
908	ZnS@BSA Nanoclusters Potentiate Efficacy of Cancer Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2104037.	11.1	89
909	Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 694409.	1.3	10
910	Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1397-1411.	0.8	9
911	Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. <i>Seminars in Interventional Radiology</i> , 2021, 38, 432-437.	0.3	3
912	Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5295.	1.7	9
913	Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 1136-1148.	0.8	2
914	The Immunology of Hepatocellular Carcinoma. <i>Vaccines</i> , 2021, 9, 1184.	2.1	41
915	Radioembolization in the Setting of Systemic Therapies. <i>Seminars in Interventional Radiology</i> , 2021, 38, 472-478.	0.3	1
916	Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. <i>Frontiers in Oncology</i> , 2021, 11, 756672.	1.3	12
917	Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review. <i>Digestive Diseases</i> , 2022, 40, 565-580.	0.8	4
918	Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. <i>Expert Opinion on Drug Safety</i> , 2021, , 1-10.	1.0	1

#	ARTICLE	IF	CITATIONS
919	The ITA.LI.CA Consortium: how multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence.. Annals of Hepatology, 2021, , 100564.	0.6	1
920	Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib. OncoTargets and Therapy, 2021, Volume 14, 5019-5026.	1.0	4
921	The management of post-transplantation recurrence of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 1-16.	4.5	27
922	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy â€“ development and validation of the CRAFTY score. Journal of Hepatology, 2022, 76, 353-363.	1.8	132
923	Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharmaceutica Sinica B, 2021, 11, 3727-3739.	5.7	34
924	Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 9-21.	4.2	29
925	Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1233-1240.	1.8	71
926	Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naïve unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. BMC Cancer, 2021, 21, 1126.	1.1	29
927	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International, 0, , .	0.2	3
928	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Frontiers in Oncology, 2021, 11, 737497.	1.3	22
929	Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Frontiers in Immunology, 2021, 12, 754961.	2.2	16
930	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. Current Opinion in Oncology, 2022, 34, 95-106.	1.1	9
931	Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Scientific Reports, 2021, 11, 19711.	1.6	9
932	Î²-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation. Frontiers in Oncology, 2021, 11, 747282.	1.3	11
933	Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines, 2021, 9, 1524.	1.4	10
934	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. JGH Open, 2021, 5, 1266-1274.	0.7	9
935	Lobar Radioembolization for Intermediate and Advanced Hepatocellular Carcinoma: Retrospective and Prospective Data. Seminars in Interventional Radiology, 2021, 38, 412-418.	0.3	1
936	Hepatocellular Carcinoma Immunotherapy. Annual Review of Medicine, 2022, 73, 267-278.	5.0	86

#	ARTICLE	IF	CITATIONS
937	Integrated bioinformatics analyses of key genes involved in hepatocellular carcinoma immunosuppression. <i>Oncology Letters</i> , 2021, 22, 830.	0.8	10
938	The inhibitory effect and mechanism of quetiapine on tumor progression in hepatocellular carcinoma in vivo. <i>Environmental Toxicology</i> , 2022, 37, 92-100.	2.1	6
939	Updates in the Systemic Treatment of Hepatocellular Carcinoma. <i>Oncology &amp; Hematology Review</i> , 2018, 14, 76.	0.2	0
940	Advances in Research on Immunological Checkpoint Inhibitors in Immunotherapy of Liver Cancer. <i>International Journal of Clinical Medicine</i> , 2019, 10, 62-69.	0.1	0
941	Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. <i>World Journal of Meta-analysis</i> , 2019, 7, 80-95.	0.1	2
942	Immunotherapy for hepatocellular cancer: beginning and future perspectives. <i>Meditinskiy Sovet</i> , 2019, , 15-21.	0.1	5
943	The Management of Hepatocellular Carcinoma. , 2020, , 237-271.		1
944	Second-line treatment of hepatocellular carcinoma: from theory to practical issues. <i>Meditinskiy Sovet</i> , 2019, , 30-36.	0.1	2
946	Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 3-15.	0.6	3
947	Systemic therapy of hepatocellular carcinoma: reality and prospects. <i>Annals of HPB Surgery</i> , 2020, 25, 27-38.	0.1	2
948	Immunotherapy in hepatocellular carcinoma: Combination strategies. <i>World Journal of Meta-analysis</i> , 2020, 8, 190-209.	0.1	1
949	Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 501-504.	0.7	0
950	Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1281-1295.	1.8	10
952	Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. <i>Cancers</i> , 2021, 13, 5448.	1.7	5
953	CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 759565.	2.2	29
954	Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. <i>Pharmaceutics</i> , 2021, 13, 1811.	2.0	8
955	Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. <i>Cancers</i> , 2021, 13, 5475.	1.7	10
956	Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	6

#	ARTICLE	IF	CITATIONS
957	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <i>Clinical Immunology</i> , 2021, 232, 108873.	1.4	19
958	Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 149-158.	1.9	5
959	Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.. <i>Journal of Hepatology</i> , 2021, , .	1.8	3
960	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. <i>International Immunopharmacology</i> , 2021, 101, 108322.	1.7	18
962	Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?. <i>Annals of Translational Medicine</i> , 2020, 8, 1701-1701.	0.7	2
963	Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.2	4
964	Applications of Antibodies in Therapy, Diagnosis, and Science. <i>Learning Materials in Biosciences</i> , 2021, , 129-159.	0.2	0
965	Pediatric hepatocellular carcinoma - the main differences from adult patients. <i>Annals of HPB Surgery</i> , 2020, 25, 85-94.	0.1	0
966	Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. <i>Current Drug Metabolism</i> , 2020, 21, 866-884.	0.7	8
967	Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. , 2020, 38, 89-91.		1
968	Liver Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 227-241.	0.8	8
970	Therapeutic Vaccines for Gastrointestinal Malignancies. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 113-158.	0.2	1
972	Hepatocellular Carcinoma: Western Experience. , 2020, , 81-118.		0
973	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
974	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A New Era in Treatment of Advanced Disease. <i>Sohag Medical Journal (SMJ)</i> , 2020, 24, 20-26.	0.1	0
975	Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. <i>Frontiers in Oncology</i> , 2021, 11, 747950.	1.3	33
976	Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. <i>Cancer Cell International</i> , 2021, 21, 589.	1.8	17
977	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 53-81.	1.3	6

#	ARTICLE	IF	CITATIONS
978	Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5586.	1.7	13
979	Clinical significance of herpes virus entry mediator expression in hepatitis B virus-related hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 19.	0.8	8
980	Clinical research progress of immune checkpoint inhibitors in treatment of primary liver cancer. <i>World Chinese Journal of Digestology</i> , 2020, 28, 605-616.	0.0	0
981	Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. <i>Digestive Disease Interventions</i> , 2020, 04, 373-381.	0.3	0
982	Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. <i>Current Gene Therapy</i> , 2020, 20, 84-99.	0.9	11
983	Drugs in Development for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2018, 14, 542-544.	0.2	1
984	The Use of Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2019, 15, 48-50.	0.2	1
985	Current and Future Systemic Therapies for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2019, 15, 266-272.	0.2	9
986	Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. <i>American Journal of Cancer Research</i> , 2019, 9, 1536-1545.	1.4	38
987	Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. <i>American Journal of Cancer Research</i> , 2020, 10, 1085-1102.	1.4	2
988	Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 1522-1533.	1.4	4
989	Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 1658-1667.	1.4	8
990	Recent progress in treatment of hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 2993-3036.	1.4	55
991	Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 3157-3178.	1.4	8
992	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. <i>Annals of Translational Medicine</i> , 2020, 8, 1532.	0.7	0
993	Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience. <i>American Journal of Cancer Research</i> , 2020, 10, 4547-4560.	1.4	3
994	Targeting the eicosanoid pathway in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 2456-2476.	1.4	1
995	Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1745-1745.	0.7	2

#	ARTICLE	IF	CITATIONS
996	Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database. <i>Cancer Medicine</i> , 2021, 10, 8754-8762.	1.3	10
997	The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 1185-1198.	1.8	35
998	Long non-coding RNA HOMER3-AS1 drives hepatocellular carcinoma progression via modulating the behaviors of both tumor cells and macrophages. <i>Cell Death and Disease</i> , 2021, 12, 1103.	2.7	14
999	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene. <i>Journal of Personalized Medicine</i> , 2021, 11, 1199.	1.1	4
1000	Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 783236.	2.2	66
1001	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665.	1.7	5
1002	Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. <i>Stem Cell Investigation</i> , 2021, 8, 22-22.	1.3	1
1003	Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. <i>Immunotherapy</i> , 2021, , .	1.0	0
1004	Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. , 2021, 9, e003195.		3
1005	Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12947.	1.8	4
1006	Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 101, 108340.	1.7	23
1007	Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 751159.	1.3	16
1008	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
1009	Risk of HBV reactivation during therapies for HCC: A systematic review. <i>Hepatology</i> , 2022, 75, 1257-1274.	3.6	26
1010	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. <i>Cancers</i> , 2021, 13, 5797.	1.7	13
1011	Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. <i>International Immunopharmacology</i> , 2021, 101, 108337.	1.7	3
1012	Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2021, 409, 112910.	1.2	13
1013	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. <i>ESMO Open</i> , 2021, 6, 100330.	2.0	25



#	ARTICLE	IF	CITATIONS
1014	Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 361-369.	1.9	68
1016	Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110638.	0.8	10
1017	Progress in the Treatment of Hepatocellular Carcinoma Complicated with Portal Vein Tumor Thrombus. <i>Advances in Clinical Medicine</i> , 2021, 11, 6018-6023.	0.0	0
1018	Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Practice</i> , 2021, 8, 127.	0.2	2
1019	Immunotherapy in Gastrointestinal Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 259-272.	0.8	3
1020	HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 62-69.	0.4	4
1021	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1022	Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1243-1255.	0.4	67
1023	Immunotherapy in older patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2022, 162, 76-98.	1.3	8
1024	Organoids as research models for hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2022, 411, 112987.	1.2	7
1025	Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 213-219.	0.8	10
1026	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. <i>Annals of Translational Medicine</i> , 2020, 8, 1532-1532.	0.7	2
1027	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
1028	Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 1347.	1.1	3
1029	Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. <i>Annals of Hepatology</i> , 2022, 27, 100677.	0.6	5
1030	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 401-413.	1.9	9
1031	Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. <i>Bioscience Reports</i> , 2022, 42, .	1.1	13
1032	Clinical pharmacology: Current innovations and future challenges. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 456-467.	1.0	2

#	ARTICLE	IF	CITATIONS
1033	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. <i>Cancers</i> , 2022, 14, 621.	1.7	34
1034	A Preliminary Study on Fructus Aurantii Extract Against Hepatocarcinoma via Glycolysis and PD-1/PD-L1 Pathway. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 2, 100051.	0.5	0
1035	EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 780509.	2.2	2
1036	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. <i>Future Oncology</i> , 2022, 18, 1423-1435.	1.1	14
1037	Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 208-218.	3.7	105
1038	Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. , 2022, 10, e003133.		20
1039	Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. <i>Seminars in Cancer Biology</i> , 2022, 86, 799-815.	4.3	28
1040	Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: Is less more?. <i>Hepatology</i> , 2022, 75, 508-510.	3.6	1
1041	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	3.6	68
1042	Hepatic Tumor Stiffness Measured by Shear Wave Elastography is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1043	Recent advances in systemic therapy for hepatocellular carcinoma. <i>Biomarker Research</i> , 2022, 10, 3.	2.8	94
1044	Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. <i>Frontiers in Immunology</i> , 2022, 13, 815575.	2.2	63
1045	Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 800679.	1.6	2
1046	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 219-229.	3.7	79
1047	Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 657512.	1.3	16
1048	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 786174.	1.6	8
1049	Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 781660.	2.2	21
1050	A hepatocellularis carcinoma komplex kezel�se.. <i>Orvosi Hetilap</i> , 2022, 162, 2-31.	0.1	1

#	ARTICLE	IF	CITATIONS
1051	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	5.1	526
1052	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. <i>Hepatology</i> , 2022, 76, 630-645.	3.6	13
1053	The new insight of treatment in Cholangiocarcinoma. <i>Journal of Cancer</i> , 2022, 13, 450-464.	1.2	18
1054	Targets of immunotherapy for hepatocellular carcinoma: An update. <i>World Journal of Hepatology</i> , 2022, 14, 140-157.	0.8	7
1055	Potential therapeutic strategies to combat HCC. <i>Current Molecular Pharmacology</i> , 2022, 15, .	0.7	1
1056	The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma. <i>Laboratory Investigation</i> , 2022, 102, 613-620.	1.7	2
1058	A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 820446.	1.6	6
1059	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. <i>Journal of Personalized Medicine</i> , 2022, 12, 149.	1.1	14
1060	Evaluation of immune-modulating drugs for use in drug-eluting microsphere transarterial embolization. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121466.	2.6	9
1061	The Prognostic Value of Albumin-Globulin Ratio and Eosinophil-Neutrophil Ratio in Patients with Advanced Tumors Undergoing Treatment with PD-1/PD-L1 Inhibitors. <i>Nutrition and Cancer</i> , 2022, 74, 2815-2828.	0.9	4
1062	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. <i>Future Oncology</i> , 2022, , .	1.1	4
1063	Preclinical mouse models of hepatocellular carcinoma: An overview and update. <i>Experimental Cell Research</i> , 2022, 412, 113042.	1.2	4
1064	Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists. <i>Diagnostics</i> , 2022, 12, 395.	1.3	2
1065	T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 203-214.	2.3	1
1066	C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients. <i>Frontiers in Immunology</i> , 2022, 13, 808101.	2.2	19
1067	Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. <i>Cancer Cell International</i> , 2022, 22, 73.	1.8	21
1068	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. <i>Digestive and Liver Disease</i> , 2022, 54, 452-460.	0.4	38
1069	Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma. <i>Aging</i> , 2022, 14, 1473-1491.	1.4	10

#	ARTICLE	IF	CITATIONS
1070	Immunotherapies for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2022, 11, 571-591.	1.3	29
1071	Camrelizumab: an investigational agent for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 337-346.	1.9	6
1072	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 801379.	1.3	21
1073	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. <i>International Journal of Biological Sciences</i> , 2022, 18, 2775-2794.	2.6	27
1074	Immunotherapy in GI Cancers: Hepatocellular Carcinoma: Perspective. , 2022, , 177-183.		0
1075	Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. <i>Advances in Cancer Research</i> , 2022, , 367-413.	1.9	6
1076	Implications of genetic heterogeneity in hepatocellular cancer. <i>Advances in Cancer Research</i> , 2022, , 103-135.	1.9	5
1077	A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210751.	0.8	21
1078	Advances in the Application of Tumor Mutation Burden in Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2022, 12, 1724-1729.	0.0	0
1079	A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 4719-4736.	1.0	1
1080	Neurological complications of GI cancers. , 2022, , 365-386.		0
1081	Long-term remission by nivolumab monotherapy for sorafenib-refractory hepatocellular carcinoma. <i>Journal of Cancer Research and Practice</i> , 2022, 9, 41.	0.2	1
1082	Role of transcription factors in hepatocellular carcinoma. , 2022, , 149-163.		0
1083	Down-regulation of TRPV6 Is Associated With Adverse Prognosis in Hepatocellular Carcinoma Treated With Curative Resection. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 259-269.	1.0	1
1084	PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA. <i>Future Oncology</i> , 2022, 18, 1691-1703.	1.1	4
1085	A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	0
1086	Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 824208.	1.3	28
1087	Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 842220.	1.8	8

#	ARTICLE	IF	CITATIONS
1088	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
1089	Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 810269.	1.3	14
1090	Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, 97.	1.8	7
1091	Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma. <i>Annals of HPB Surgery</i> , 2022, 27, 33-39.	0.1	0
1092	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435.	1.9	3
1093	Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?. <i>Seminars in Cancer Biology</i> , 2022, 86, 1175-1185.	4.3	2
1094	Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2371-2379.	2.0	4
1095	Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. <i>Clinical Cancer Research</i> , 2022, 28, 3499-3508.	3.2	32
1096	Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 157-170.	1.8	23
1097	OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2677-2689.	2.0	7
1098	Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 233-263.	1.8	27
1099	Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2631-2643.	2.0	23
1100	Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. <i>Annals of Medicine</i> , 2022, 54, 803-811.	1.5	9
1102	Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 814120.	1.3	3
1103	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. <i>Cancers</i> , 2022, 14, 1760.	1.7	20
1104	Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, 1441.	5.8	28
1105	Immunotherapy and Transarterial therapy of <sc>HCC</sc>: What the interventional radiologist needs to know about the changing landscape of <sc>HCC</sc> treatment?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 478-482.	0.9	10
1106	Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. <i>Frontiers in Oncology</i> , 2022, 12, 764923.	1.3	4

#	ARTICLE	IF	CITATIONS
1107	Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition). <i>Liver Cancer</i> , 2022, 11, 315-328.	4.2	31
1108	Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do?. <i>Frontiers in Oncology</i> , 2022, 12, 824799.	1.3	3
1109	ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 842351.	1.1	8
1110	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 253-264.	1.5	20
1111	Immune-related lincRNA pairs predict prognosis and therapeutic response in hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, 4259.	1.6	1
1112	SIRP $\alpha$ and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, 140.	1.8	21
1113	Comparative safety, efficacy and survival outcome of anti-PD-1 immunotherapy in colorectal cancer patients with vs without hepatitis B virus infection: a multicenter cohort study. <i>Clinical and Translational Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.3	6
1114	Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1526.	1.7	7
1115	Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 483-494.	1.9	2
1116	Prognostic significance of <scp>albumin</scp> bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 662-670.	0.9	5
1117	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 821903.	1.3	2
1118	Phase II Clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Future Oncology</i> , 2022, 18, 2173-2191.	1.1	1
1119	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. <i>Cancers</i> , 2022, 14, 1747.	1.7	36
1120	The Treatment Landscape of Advanced Hepatocellular Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 917-927.	1.8	21
1121	LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 203-220.	1.8	8
1122	Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2449-2460.	3.2	39
1123	Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 807102.	1.3	18
1124	Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1752-1763.	1.9	3

#	ARTICLE	IF	CITATIONS
1125	Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape. Journal of the Formosan Medical Association, 2022, 121, 1371-1383.	0.8	3
1126	Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model. Experimental Hematology and Oncology, 2022, 11, 20.	2.0	6
1127	Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl) Tj ETQq0 0 0 2gBT /Overclock 10 Tf	0.8	2
1128	Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology, 2022, 75, 1604-1626.	3.6	97
1129	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European Journal of Cancer, 2022, 167, 1-12.	1.3	43
1130	Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology, 2022, 42, 101748.	0.8	2
1131	Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence. Engineering, 2022, 10, 57-64.	3.2	4
1132	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life, 2021, 11, 1355.	1.1	8
1133	Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Immunology, 2021, 12, 794099.	2.2	34
1134	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. Frontiers in Immunology, 2021, 12, 773168.	2.2	18
1135	Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdominal Radiology, 2022, 47, 969-980.	1.0	11
1136	Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Frontiers in Oncology, 2021, 11, 798832.	1.3	16
1137	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 803133.	1.3	83
1138	Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria. Frontiers in Oncology, 2021, 11, 764189.	1.3	12
1139	Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 6307.	1.7	17
1140	Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers, 2021, 13, 6337.	1.7	3
1141	A targetable LIFR~NF-~B~LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature Communications, 2021, 12, 7333.	5.8	117
1142	Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e2136128.	2.8	29

#	ARTICLE	IF	CITATIONS
1143	Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 781307.	1.6	10
1144	Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies. <i>Medicine (United States)</i> , 2021, 100, e28113.	0.4	5
1145	Second-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-majority NCI-designated cancer center. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2943-2951.	0.6	3
1146	Embrrolizumab as second line therapy for hepatocellular patient. <i>Meditsinskiy Sovet</i> , 2021, , 150-154.	0.1	0
1147	Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. <i>Frontiers in Immunology</i> , 2021, 12, 792781.	2.2	39
1148	A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China. <i>Frontiers in Oncology</i> , 2021, 11, 788635.	1.3	9
1149	Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis. <i>Medicine (United States)</i> , 2021, 100, e27987.	0.4	3
1150	Stable liver graft post anti-EPD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma. <i>Pediatric Transplantation</i> , 2022, 26, e14209.	0.5	11
1151	Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2038-2049.	0.8	3
1152	Comprehensive analysis of spatial architecture in primary liver cancer. <i>Science Advances</i> , 2021, 7, eabg3750.	4.7	113
1153	Biological therapies in patients with liver disease: are they really lifesavers?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 473-490.	1.4	0
1155	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. <i>Cancer Medicine</i> , 2022, 11, 602-617.	1.3	1
1156	Frontline therapy for advanced hepatocellular carcinoma: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210861.	1.4	13
1157	Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. <i>BioScience Trends</i> , 2022, 16, 130-141.	1.1	14
1158	Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. <i>Future Oncology</i> , 2022, 18, 2269-2288.	1.1	12
1159	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	3.6	18
1160	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	3.2	31
1161	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	3.2	32



#	ARTICLE	IF	CITATIONS
1162	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. <i>Cancers</i> , 2022, 14, 2056.	1.7	24
1163	Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 333-339.	1.4	65
1164	Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 315-325.	1.8	5
1165	Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers. <i>Frontiers in Immunology</i> , 2022, 13, 810539.	2.2	4
1166	Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114376.	2.6	3
1167	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2018.	1.7	15
1168	Systemic Therapy in Metastatic Hepatocellular Carcinoma. <i>Current Gastroenterology Reports</i> , 2022, 24, 65-71.	1.1	4
1169	Efficacy and safety of <sc>PD</sc> inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. <i>Cancer Medicine</i> , 2022, 11, 3612-3622.	1.3	13
1170	Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 874473.	1.3	22
1187	Updates on clinical trials for the management of hepatocellular carcinoma. , 2022, , 259-273.		0
1188	Recent advances in medical treatment of hepatocellular cancer. , 2022, , 365-375.		0
1189	Immunotherapy for hepatocellular cancer: a review of current status. , 2022, , 245-258.		0
1190	Research Progress of Immune Checkpoint Inhibitors in the Treatment of Primary Liver Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 3360-3366.	0.0	0
1191	Immune checkpoint inhibitors for hepatocellular carcinoma. , 2022, , 215-223.		0
1192	Therapeutic options for the management of hepatocellular carcinoma. , 2022, , 43-62.		0
1193	Precision medicine approaches for treating hepatocellular carcinoma. , 2022, , 287-299.		0
1194	Resistance of Lenvatinib in hepatocellular carcinoma. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	5
1195	Apoptosis-Related Signature Predicts Prognosis and Immune Microenvironment Infiltration in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 818403.	1.1	3

#	ARTICLE	IF	CITATIONS
1196	Tumour burden score and immune-related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. <i>Liver Cancer International</i> , 0, .	0.2	0
1197	Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2022, 10, 728-744.	1.6	27
1198	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. <i>Investigational New Drugs</i> , 2022, 40, 789-797.	1.2	14
1199	Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. <i>Cancers</i> , 2022, 14, 2357.	1.7	18
1200	Immunotherapy-Based Treatments of Hepatocellular Carcinoma: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 219, 533-546.	1.0	6
1201	Prediction of Drug-Drug Interaction Using an Attention-Based Graph Neural Network on Drug Molecular Graphs. <i>Molecules</i> , 2022, 27, 3004.	1.7	13
1202	Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
1203	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126
1204	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	2.0	7
1206	Immune cell infiltration and immunotherapy in hepatocellular carcinoma. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 7178-7200.	1.0	2
1207	Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 50-57.	0.4	1
1208	Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1197-1206.	1.4	13
1209	Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
1210	Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 693-706.	1.9	2
1211	Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 1606-1620.	1.4	0
1212	Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/ $\beta$ -catenin signal activation. <i>Oncology Letters</i> , 2022, 24, .	0.8	8
1218	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. <i>Current Research in Immunology</i> , 2022, 3, 118-127.	1.2	20
1219	An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 0, , .	1.3	5

#	ARTICLE	IF	CITATIONS
1220	Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1221	Indonesian consensus on systemic therapies for hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 263-274.	0.7	1
1222	Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	22
1223	Comprehensive Analyses of MELK-Associated ceRNA Networks Reveal a Potential Biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
1224	Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	2
1225	Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent—Based Combinations. <i>Journal of Clinical Oncology</i> , 2022, 40, 2763-2773.	0.8	18
1226	Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. <i>Korean Journal of Transplantation</i> , 2022, 36, 82-98.	0.0	9
1227	Emerging drugs for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 141-149.	1.0	4
1228	First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. <i>Biomedicines</i> , 2022, 10, 1304.	1.4	9
1229	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	17
1230	Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors. <i>Advanced Science</i> , 2022, 9, .	5.6	17
1231	Complete response by patients with advanced hepatocellular carcinoma after combination immune/targeted therapy and transarterial chemoembolization: two case reports and literature review. <i>Translational Cancer Research</i> , 2021, .	0.4	1
1232	Interventional oncology update. <i>European Journal of Radiology Open</i> , 2022, 9, 100430.	0.7	2
1233	Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. <i>Liver Cancer</i> , 2022, 11, 426-439.	4.2	11
1234	The advanced development of molecular targeted therapy for hepatocellular carcinoma. <i>Cancer Biology and Medicine</i> , 2022, 19, 1-16.	1.4	18
1235	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26
1236	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. <i>Hepatology International</i> , 2022, 16, 1150-1160.	1.9	35
1237	Imaging for better responses to immunotherapy in hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 6-9.	3.6	1

#	ARTICLE	IF	CITATIONS
1238	Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 23-37.	1.4	7
1239	Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1103-1114.	0.8	8
1241	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
1242	Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1243	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	19
1244	Four-Pyroptosis Gene-Based Nomogram as a Novel Strategy for Predicting the Effect of Immunotherapy in Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2022, 2022, 1-24.	0.9	2
1245	Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma. <i>Meditinskiy Sovet</i> , 2022, , 157-162.	0.1	0
1247	The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF- $\kappa$ B Signaling. <i>Medicina (Lithuania)</i> , 2022, 58, 798.	0.8	3
1248	Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. <i>World Journal of Hepatology</i> , 2022, 14, 1074-1086.	0.8	1
1249	Holliday Cross-Recognition Protein HJURP: Association With the Tumor Microenvironment in Hepatocellular Carcinoma and With Patient Prognosis. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	6
1250	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 448-472.	0.9	6
1251	MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. <i>Cancers</i> , 2022, 14, 2880.	1.7	7
1252	Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
1253	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	1.4	10
1254	ICIs-Related Cardiotoxicity in Different Types of Cancer. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 203.	0.8	11
1255	Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti- $\alpha$ VEGF/TKI and immunotherapy. <i>Hepatology</i> , 2022, 76, 1203-1218.	3.6	22
1256	Emerging insights on immunotherapy in liver cancer. <i>Antioxidants and Redox Signaling</i> , 0, , .	2.5	4
1257	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16

#	ARTICLE	IF	CITATIONS
1258	Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
1259	Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 969-978.	1.2	9
1260	The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. <i>Revista De Gastroenterología De México (English Edition)</i> , 2022, , .	0.1	0
1261	Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	6
1262	Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 571-581.	1.8	10
1263	Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. <i>Cancers</i> , 2022, 14, 3213.	1.7	10
1264	Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1265	The focus clinical research in intrahepatic cholangiocarcinoma. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	7
1266	Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. <i>Liver Cancer</i> , 2022, 11, 558-571.	4.2	6
1267	Cold Atmospheric Plasma Conveys Selectivity Against Hepatocellular Carcinoma Cells via Triggering EGFR(Tyr1068)-Mediated Autophagy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1268	Necroptosis-Related Genes Signatures Identified Molecular Subtypes and Underlying Mechanisms in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1269	Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 226-244.	2.0	4
1270	Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1271	Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
1272	Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs. <i>Clinical Cancer Research</i> , 2022, 28, 3405-3407.	3.2	2
1273	Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1049-1060.	3.7	3
1274	Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	4
1275	Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. <i>Cancers</i> , 2022, 14, 3373.	1.7	17

#	ARTICLE	IF	CITATIONS
1276	Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. <i>Annals of Hepatology</i> , 2022, 27, 100740.	0.6	1
1277	Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2022, 29, 1951-1960.	2.2	17
1278	Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition). <i>Liver Cancer</i> , 2022, 11, 511-526.	4.2	11
1279	Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. <i>European Radiology</i> , 2023, 33, 512-522.	2.3	15
1280	Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	1.4	8
1281	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists's Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.2	1
1282	Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma. <i>Immunogenetics</i> , 0, , .	1.2	1
1283	Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. <i>Cytokine and Growth Factor Reviews</i> , 2022, 67, 1-10.	3.2	4
1284	A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma. <i>Cells</i> , 2022, 11, 2302.	1.8	4
1285	Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. <i>World Journal of Gastroenterology</i> , 2022, 28, 3573-3585.	1.4	4
1286	Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 371-384.	2.0	7
1287	Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	0
1288	Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC. <i>BMJ Case Reports</i> , 2022, 15, e250009.	0.2	1
1289	Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1290	The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 4874.	1.0	5
1292	DNA methylation regulators-related molecular patterns and tumor immune landscape in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1293	Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. <i>Cancers</i> , 2022, 14, 3892.	1.7	1
1294	Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. <i>Liver Cancer</i> , 2023, 12, 44-56.	4.2	1

#	ARTICLE	IF	CITATIONS
1295	Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-27.	0.9	1
1297	Biomarkers for response to immunotherapy in hepatobiliary malignancies. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 413-419.	0.6	12
1298	Comprehensive analysis of the cancer driver genes constructs a seven-gene signature for prediction of survival and tumor immunity in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
1299	A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
1300	Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2023, 23, 579-590.	1.9	6
1301	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1302	Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1303	Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
1304	Advances in novel systemic therapies for advanced hepatocellular carcinoma. <i>Future Medicinal Chemistry</i> , 0, , .	1.1	1
1305	Interventional radiology meets immuno-oncology for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, , .	1.8	5
1306	Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 855-867.	1.8	5
1307	Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1308	Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial. <i>Hepatology International</i> , 2022, 16, 1179-1187.	1.9	6
1309	Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy. <i>Radiation Medicine and Protection</i> , 2022, , .	0.4	1
1310	Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 420-429.	0.6	9
1311	Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
1312	The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 1773-1796.	3.6	101
1313	A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	3

#	ARTICLE	IF	CITATIONS
1314	Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. <i>Current Oncology</i> , 2022, 29, 5489-5507.	0.9	19
1315	Comprehensive bioinformatic analysis of MMP1 in hepatocellular carcinoma and establishment of relevant prognostic model. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
1316	Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. <i>European Journal of Cancer</i> , 2022, 174, 68-77.	1.3	45
1317	Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
1318	Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10038.	1.8	4
1319	Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1320	Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1011-1027.	1.8	3
1321	Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2023, 164, 72-88.e18.	0.6	48
1322	Immune checkpoint inhibitor therapy for hepatocellular carcinoma. <i>Annals of Gastroenterology</i> , 2022, , .	0.4	0
1323	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1324	Available Immunotherapy Drugs in Oncology. <i>Current Clinical Pathology</i> , 2022, , 5-23.	0.0	0
1325	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. <i>Cancer Control</i> , 2022, 29, 107327482211112.	0.7	17
1326	Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities. <i>Hepatoma Research</i> , 0, 8, 32.	0.6	0
1327	Identification of circadian clock genes as regulators of immune infiltration in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2022, 13, 3199-3208.	1.2	4
1328	Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. , 2022, , 761-776.		0
1329	Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2023, 12, 116-128.	4.2	5
1330	Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. <i>Cancers</i> , 2022, 14, 4201.	1.7	1
1331	PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2



#	ARTICLE	IF	CITATIONS
1333	Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
1334	Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. <i>Discover Oncology</i> , 2022, 13, .	0.8	6
1335	Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
1336	Role of genetic testing in hepatic, pancreatic, and biliary cancers. <i>Surgical Oncology</i> , 2022, 44, 101844.	0.8	7
1337	A retrospective study of PD-L1 immunohistochemistry for hepatocellular carcinoma. , 2022, 1, 187-193.		1
1338	The immune landscape of hepatocellular carcinoma—where we are? (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	6
1340	Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. , 2022, 10, e005128.		4
1341	A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. <i>Current Oncology</i> , 2022, 29, 6445-6462.	0.9	6
1342	Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. <i>BJS Open</i> , 2022, 6, .	0.7	20
1343	Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 4929-4942.	1.4	5
1344	Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1345	Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1346	PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. <i>Biomolecules</i> , 2022, 12, 1226.	1.8	4
1347	Immunotherapy and Hepatocellular Cancer: Where Are We Now?. <i>Cancers</i> , 2022, 14, 4523.	1.7	7
1348	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	83
1349	Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1350	Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 202-213.	0.4	25
1351	Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>Cancers</i> , 2022, 14, 4631.	1.7	12

#	ARTICLE	IF	CITATIONS
1353	Neoantigens and their clinical applications in human gastrointestinal cancers. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
1354	Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
1355	Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4616.	1.7	18
1356	Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11363.	1.8	6
1357	Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1622-1636.	0.8	6
1358	Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1359	Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1079-1094.	1.0	4
1360	SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of $\langle i \rangle PD1 \langle /i \rangle$ mRNA. <i>Future Oncology</i> , 0, . .	1.1	3
1361	Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. <i>JCO Global Oncology</i> , 2022, , .	0.8	4
1362	Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
1363	Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety. <i>Liver Cancer</i> , 2023, 12, 145-155.	4.2	2
1364	Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 4819-4826.	2.6	2
1365	Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. <i>Liver Cancer</i> , 2023, 12, 72-84.	4.2	16
1366	Research Progress of Systematic Therapy for Advanced Primary Liver Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 9622-9627.	0.0	0
1367	Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211313.	0.8	6
1368	Research Advancements in Hepatocellular Carcinoma and Ferroptosis. <i>Advances in Clinical Medicine</i> , 2022, 12, 9363-9368.	0.0	0
1369	Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211336.	0.8	4
1370	Pembrolizumab-induced esophagitis dissecans superficialis in a patient with squamous cell lung carcinoma. <i>Annals of Cancer Research and Therapy</i> , 2022, 30, 121-124.	0.1	1

#	ARTICLE	IF	CITATIONS
1371	First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review. <i>Current Oncology</i> , 2022, 29, 7305-7326.	0.9	2
1372	Hepatocellular Carcinoma Medical Therapy. <i>Updates in Surgery Series</i> , 2023, , 173-179.	0.0	0
1373	Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. <i>World Journal of Hepatology</i> , 0, 14, 1862-1874.	0.8	5
1374	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1109-1125.	1.8	11
1375	Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. <i>Pharmaceutics</i> , 2022, 14, 2263.	2.0	3
1376	Immunotherapy and Hepatocellular Carcinoma. , 0, , .		0
1377	Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1378	Single-cell transcriptomics reveals the role of Macrophage- $\text{Na}^+\text{ve}$ $\text{CD4}^+\text{T}$ cell interaction in the immunosuppressive microenvironment of primary liver carcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
1379	Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2- <i>b</i> ]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 14809-14831.	2.9	5
1380	Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 1341-1351.	1.0	9
1381	Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle. <i>Cancers</i> , 2022, 14, 4896.	1.7	4
1382	Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma. <i>Clinical Radiology</i> , 2023, 78, e37-e44.	0.5	1
1383	Sex Differences in Genomic Features of Hepatitis B-associated Hepatocellular Carcinoma With Distinct Antitumor Immunity. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 327-354.	2.3	5
1384	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 583-705.	4.5	102
1385	Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5013.	1.7	12
1387	bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	0
1388	Nanohydroxyapatite Stimulates PD-L1 Expression to Boost Melanoma Combination Immunotherapy. <i>ACS Nano</i> , 2022, 16, 18921-18935.	7.3	3
1389	An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10

#	ARTICLE	IF	CITATIONS
1390	Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention. <i>Cell Proliferation</i> , 2023, 56, .	2.4	16
1391	Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1392	Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1393	Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5173.	1.7	6
1396	Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. , 2022, 10, e005414.		18
1397	Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1149-1169.	1.8	3
1398	An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2023, 32, 101-117.	0.6	4
1400	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <i>PLoS ONE</i> , 2022, 17, e0272022.	1.1	4
1401	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
1402	Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211348.	0.6	2
1403	Advances in Targeted Immunotherapy for Hepatobiliary Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13961.	1.8	10
1404	Evolving therapeutic landscape of advanced hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 203-222.	8.2	113
1405	Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. <i>World Journal of Transplantation</i> , 0, 12, 331-346.	0.6	2
1406	Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1407	Have We Found the "Holy Grail" That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2023, 164, 15-18.	0.6	0
1408	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead? A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14117.	1.8	7
1409	Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1171-1185.	1.8	3
1410	Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1

#	ARTICLE	IF	CITATIONS
1411	Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-32.	0.9	2
1412	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1413	Low-dose nivolumab in advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
1414	Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. <i>Liver Cancer International</i> , 2023, 4, 13-27.	0.2	0
1415	Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e31479.	0.4	2
1416	Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. , 2022, 1, 225-234.		3
1418	Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	1
1419	Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
1421	Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. <i>Advances in Therapy</i> , 0, , .	1.3	1
1422	Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2022, 18, 3769-3782.	1.1	11
1423	Evolution of systemic therapy for advanced-stage hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 899-902.	0.7	1
1424	Molecular subtyping and IMScore based on immune-related pathways, oncogenic pathways, and DNA damage repair pathways for guiding immunotherapy in hepatocellular carcinoma patients. <i>Journal of Gastrointestinal Oncology</i> , 2022, .	0.6	1
1425	Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review. <i>Journal of Cancer</i> , 2022, 13, 3539-3553.	1.2	2
1426	A new and rare type of hepatocellular carcinoma: Survival and gene analysis of portal vein tumour thrombus-type hepatocellular carcinoma. <i>Pathology Research and Practice</i> , 2023, 241, 154260.	1.0	0
1427	Research progress on the role of cholesterol in hepatocellular carcinoma. <i>European Journal of Pharmacology</i> , 2023, 938, 175410.	1.7	4
1428	Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188841.	3.3	0
1429	Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188848.	3.3	3
1430	The role of circadian gene timeless in gastrointestinal cancers. <i>Gene Reports</i> , 2023, 30, 101722.	0.4	0

#	ARTICLE	IF	CITATIONS
1431	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2022, 23, 1126.	1.5	44
1432	The Tumor Microenvironment in Hepatocellular Carcinoma. , 2022, , 107-137.		0
1433	Interdisciplinary Approach in Hepatobiliary Cancers. , 2022, , 1-40.		0
1434	Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Frontiers in Oncology, 0, 12, .	1.3	3
1436	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Cancers, 2022, 14, 5834.	1.7	24
1437	Reduced tumor stiffness quantified by tomoelastography as a predicative marker for glypican-3-positive hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	3
1438	Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opinion on Investigational Drugs, 2022, 31, 1151-1167.	1.9	3
1439	Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis. Frontiers in Oncology, 0, 12, .	1.3	2
1440	Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1187-1200.	1.8	2
1441	Highlighting novel targets in immunotherapy for liver cancer. Expert Review of Gastroenterology and Hepatology, 2022, 16, 1029-1041.	1.4	3
1442	ACR Appropriateness Criteria® Management of Liver Cancer: 2022 Update. Journal of the American College of Radiology, 2022, 19, S390-S408.	0.9	1
1443	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2023, 41, 1434-1443.	0.8	50
1444	CD8+ T cell exhaustion and cancer immunotherapy. Cancer Letters, 2023, 559, 216043.	3.2	18
1445	The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Future Oncology, 2022, 18, 4119-4136.	1.1	4
1446	Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 2023, 29, 754-763.	3.2	10
1447	Immune Checkpoint Inhibitor Therapy in Oncology. JACC: CardioOncology, 2022, 4, 579-597.	1.7	25
1449	Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future. Current Pharmaceutical Design, 2023, 29, 2-14.	0.9	2
1450	In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer. Scientific Reports, 2022, 12, .	1.6	2

#	ARTICLE	IF	CITATIONS
1451	An overview: Management of patients with advanced hepatocellular carcinoma. <i>BioScience Trends</i> , 2022, 16, 405-425.	1.1	7
1452	Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1247-1261.	1.8	7
1453	Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1263-1278.	1.8	2
1454	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. <i>Diagnostics</i> , 2022, 12, 3157.	1.3	6
1455	Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	0
1456	Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1457	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	36
1458	Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Cancers</i> , 2023, 15, 50.	1.7	5
1459	HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response. <i>European Radiology</i> , 2023, 33, 4389-4400.	2.3	2
1460	Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. <i>Biomedicines</i> , 2022, 10, 3202.	1.4	26
1461	Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. <i>European Journal of Cell Biology</i> , 2023, 102, 151284.	1.6	8
1462	Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1463	Biomarkers Use and Development in Hepatology: Insights on the Latest Applications. <i>Cells</i> , 2023, 12, 104.	1.8	0
1464	Anti-atherogenic and cardio-protective properties of sweet melon ( <i>Cucumis melo</i> . L. <i>Inodorus</i> ) seed extract on high fat diet induced obesity in male wistar rats. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, .	1.2	2
1465	Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211480.	1.4	10
1466	Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts. <i>Modern Pathology</i> , 2023, 36, 100042.	2.9	2
1467	Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. <i>Current Oncology</i> , 2023, 30, 1363-1380.	0.9	1
1468	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13

#	ARTICLE	IF	CITATIONS
1469	Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 348.	1.7	3
1470	Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1471	A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma. <i>Cell Discovery</i> , 2023, 9, .	3.1	8
1472	Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1417.	1.8	10
1473	Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482211482.	1.4	1
1474	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1475	Phase 1 dose escalation study of <sc>FGFR4</sc> inhibitor in combination with pembrolizumab in advanced solid tumors patients. <i>Cancer Medicine</i> , 0, , .	1.3	1
1476	Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1477	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2023, 2023, 1-13.	0.6	0
1478	Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1479	Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. <i>Current Oncology</i> , 2023, 30, 749-757.	0.9	4
1480	Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. <i>Hepatology International</i> , 2023, 17, 406-416.	1.9	10
1481	In situ Vaccination Followed by Intramuscular poly-ICLC Injections for the Treatment of Hepatocellular Carcinoma in Mouse Models. <i>Pharmacological Research</i> , 2023, , 106646.	3.1	0
1482	A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-“PD-1 Immunotherapy against Hepatocarcinoma. <i>Journal of Immunology</i> , 2023, 210, 681-695.	0.4	2
1483	Soluble programmed death ligand-1 induced immunosuppressive effects on chimeric antigen receptor-“natural killer cells targeting Glypican-3 in hepatocellular carcinoma. <i>Immunology</i> , 2023, 169, 204-218.	2.0	4
1484	HMMR potential as a diagnostic and prognostic biomarker of cancer-“speculation based on a pan-cancer analysis. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	2
1485	Peripheral and tumor-“infiltrating immune cells are correlated with patient outcomes in ovarian cancer. <i>Cancer Medicine</i> , 2023, 12, 10045-10061.	1.3	1
1486	Clinical features and management issues of NAFLD-related HCC: what we know so far. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 31-43.	1.4	4



#	ARTICLE	IF	CITATIONS
1487	Microbiome and Metabolomics in Liver Cancer: Scientific Technology. <i>International Journal of Molecular Sciences</i> , 2023, 24, 537.	1.8	13
1488	Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2023, 111, 37-46.	1.0	3
1489	Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 260.	1.7	1
1490	Fibrosis and Immunotherapy in Hepatocellular Carcinoma. , 2023, , 255-281.		1
1491	Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 654.	1.7	7
1492	Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2358.	1.8	5
1493	The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1494	Tumor immunology. , 2023, , 245-452.		0
1495	The phospholipid flippase <sc>ATP9A</sc> enhances macropinocytosis to promote nutrient starvation tolerance in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2023, 260, 17-31.	2.1	3
1496	Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 854.	1.7	2
1497	Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon. <i>Hepatology</i> , 2023, 77, 1074-1077.	3.6	0
1498	Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 39-58.	0.4	1
1499	Analysis of the potential association between ferroptosis and immune in hepatocellular carcinoma and their relationship with prognosis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1500	Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. <i>Pathology Research and Practice</i> , 2023, 244, 154338.	1.0	3
1501	FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2685.	1.8	6
1502	Immunotherapies in rare cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	15
1503	Novel insights into the impact of liver inflammatory responses on primary liver cancer development. <i>Liver Research</i> , 2023, 7, 26-34.	0.5	1
1504	The application of nanoparticles in immunotherapy for hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2023, 355, 85-108.	4.8	3

#	ARTICLE	IF	CITATIONS
1505	A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). <i>Future Oncology</i> , 2022, 18, 4465-4471.	1.1	1
1506	KLF4 loss in hepatocellular carcinoma: Improving prognostic prediction and correlating immune infiltrates. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
1507	Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment. <i>European Journal of Radiology</i> , 2023, 162, 110784.	1.2	1
1508	A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma. <i>Journal of Pharmacological Sciences</i> , 2023, 152, 69-75.	1.1	1
1509	Immunotherapy for recurrent hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 2261-2271.	1.4	1
1511	Liver Stereotactic Body Radiotherapy (SBRT). , 2022, , 349-362.		0
1512	Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN- $\gamma$ /NSDHL/SREBP1/TGF- $\beta$ 1 axis in hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114254.	2.5	4
1515	Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images. <i>Oncology Research</i> , 2022, 30, 243-258.	0.6	0
1516	Hypoxia-associated circPRDM4 promotes immune escape via HIF-1 $\alpha$ regulation of PD-L1 in hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	12
1517	Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	44
1518	Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. <i>Hepatology Communications</i> , 2023, 7, e0054-e0054.	2.0	2
1519	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	19
1520	Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells. <i>Clinical and Experimental Medicine</i> , 2023, 23, 1881-1899.	1.9	1
1521	Therapeutic options in hepatocellular carcinoma: a comprehensive review. <i>Clinical and Experimental Medicine</i> , 2023, 23, 1901-1916.	1.9	11
1522	Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3625.	1.8	1
1524	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , 2023, 12, 309-320.	4.2	5
1525	Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 267-279.	1.8	1
1527	Systemic therapy in advanced hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 516-519.	4.5	3

#	ARTICLE	IF	CITATIONS
1528	Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma. <i>European Surgical Research</i> , 2023, 64, 268-277.	0.6	2
1529	T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. , 2023, 11, e006493.		4
1530	Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Advances in Therapy</i> , 2023, 40, 1686-1704.	1.3	3
1531	CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma. <i>Current Oncology</i> , 2023, 30, 2653-2672.	0.9	2
1532	Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2137-2149.	2.0	2
1533	Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 303-313.	1.8	3
1534	Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients. <i>Anticancer Research</i> , 2023, 43, 1377-1384.	0.5	1
1536	Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. <i>Immunotherapy</i> , 2023, 15, 353-365.	1.0	3
1537	Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. , 2023, 2, 36-51.		1
1538	Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. <i>Oncogene</i> , 2023, 42, 1051-1057.	2.6	4
1539	The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311597.	0.8	3
1540	Immune Strategies for Gastrointestinal Cancer: HCC. , 2023, , 163-176.		0
1541	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5002.	1.8	6
1544	Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. <i>Vaccines</i> , 2023, 11, 614.	2.1	4
1545	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
1546	Body mass index and serum alpha-fetoprotein level associated with PD1 expression and prognosis in patients with hepatocellular carcinoma. <i>Heliyon</i> , 2023, 9, e14460.	1.4	0
1547	Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. <i>Cancers</i> , 2023, 15, 1680.	1.7	8
1548	Systemic treatment for unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 1407-1424.	1.4	0

#	ARTICLE	IF	CITATIONS
1549	FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. <i>Journal of Hepatology</i> , 2023, 79, 109-125.	1.8	20
1550	The Multifaceted Roles of Macrophages in NAFLD Pathogenesis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 1311-1324.	2.3	13
1551	Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. <i>Livers</i> , 2023, 3, 121-160.	0.8	2
1552	Prognostic significance of the CRAFTY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
1553	Immunotherapy for advanced or recurrent hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 405-424.	0.8	0
1554	Systemic treatment for unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 1551-1568.	1.4	5
1555	A novel risk score model based on pyroptosis-related genes for predicting survival and immunogenic landscape in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	1
1556	A key driver to promote HCC: Cellular crosstalk in tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
1557	The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 447-457.	1.8	1
1558	Combination immunotherapy for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2023, 79, 506-515.	1.8	46
1559	Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. , 2023, , .		0
1560	Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective studies. <i>International Immunopharmacology</i> , 2023, 118, 110019.	1.7	15
1561	Exosome-derived circCCAR1 promotes CD8 <sup>+</sup> T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2023, 22, .	7.9	47
1562	Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3
1563	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
1564	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
1565	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. <i>Oncologist</i> , 2023, 28, 714-721.	1.9	2
1566	High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 16, 63-81.	2.3	1

#	ARTICLE	IF	CITATIONS
1567	The predictive value of <scp>PD-1</scp> expression in patients with advanced hepatocellular carcinoma treated with <scp>PD-1</scp> inhibitors: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2023, 12, 9282-9292.	1.3	8
1568	T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. <i>Liver Cancer International</i> , 2023, 4, 58-72.	0.2	0
1569	Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	7
1570	Management of hepatocellular carcinoma from diagnosis in routine clinical practice. <i>Hepatic Oncology</i> , 2022, 9, .	4.2	0
1571	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. <i>Biomedicines</i> , 2023, 11, 1020.	1.4	6
1572	Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1573	The Regulatory Axis of PD-L1 Isoform 2/TNF/T Cell Proliferation Is Required for the Canonical Immune-Suppressive Effects of PD-L1 Isoform 1 in Liver Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6314.	1.8	0
1574	Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion. <i>Advanced Science</i> , 2023, 10, .	5.6	18
1576	Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0
1577	Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors. <i>Digestive and Liver Disease</i> , 2023, 55, 938-944.	0.4	2
1578	Another prognostic marker for hepatocellular carcinoma. <i>Hepatology International</i> , 2023, 17, 279-280.	1.9	0
1579	Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. <i>Radiology</i> , 2023, 307, .	3.6	16
1580	Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 19, 329-339.	0.9	2
1581	Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. <i>Molecular and Cellular Biochemistry</i> , 2024, 479, 127-170.	1.4	1
1582	Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4275-4293.	2.9	7
1583	Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). <i>Liver Cancer</i> , 2023, 12, 405-444.	4.2	11
1584	Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 587-598.	1.8	1
1585	Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma. <i>Hepatology International</i> , 2023, 17, 753-764.	1.9	11

#	ARTICLE	IF	CITATIONS
1586	Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 689-699.	0.8	1
1588	Normalization of Tumor Vessels by Lenvatinib-Based Metallo-Nanodrugs Alleviates Hypoxia and Enhances Calreticulin-Mediated Immune Responses in Orthotopic HCC and Organoids. <i>Small</i> , 2023, 19, .	5.2	5
1589	Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation. <i>Engineering</i> , 2023, 29, 59-72.	3.2	8
1590	Role of ferroptosis and its non-coding RNA regulation in hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1591	Role of $\beta$ -Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 2311.	1.7	6
1592	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. <i>Pathology Research and Practice</i> , 2023, 247, 154473.	1.0	1
1594	Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. <i>Oncogenesis</i> , 2023, 12, .	2.1	1
1595	Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma. , 0, , .		0
1596	Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1597	Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7640.	1.8	5
1598	Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma. <i>Mediators of Inflammation</i> , 2023, 2023, 1-23.	1.4	3
1599	Histone chaperone SSRP1 is required for apoptosis inhibition and mitochondrial function in HCC via transcriptional promotion of TRAP1. <i>Biochemistry and Cell Biology</i> , 0, , .	0.9	0
1600	Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma. <i>Cancer Letters</i> , 2023, 563, 216192.	3.2	4
1606	Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1613	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
1644	New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma. <i>Drugs</i> , 2023, 83, 1091-1109.	4.9	2
1662	Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1684	Biomarkers for immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 780-798.	12.5	5

#	ARTICLE	IF	CITATIONS
1692	Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology, 2023, 20, 864-884.	12.5	14
1699	Amino Acids Transport as an Index of Cancer Stem Cells Dysregulation. , 2023, , 1-24.		0
1700	Hepatitis Viruses: Hepatocellular Carcinoma. , 2023, , 1-36.		0
1719	Computational immunogenomic approaches to predict response to cancer immunotherapies. Nature Reviews Clinical Oncology, 2024, 21, 28-46.	12.5	1
1785	Omics-based molecular classifications empowering in precision oncology. Cellular Oncology (Dordrecht), 0, , .	2.1	0
1807	Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment. Methods in Cell Biology, 2024, , 79-97.	0.5	0